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ABSTRACT 
Magnetic Resonance Imaging instruments rely on a contrast agent to provide high-resolution 
images of tissues in vivo. However, current clinical contrast agents are hindered by low relaxivity 
and fast correlation time, necessitating high injection dosages. These concerns, among others, 
have driven the development of a class of protein-based contrast agents (ProCAs), by design of 
lanthanide binding sites into a scaffold protein. ProCA1 has a higher reported relaxivity and 
dosage efficiency than current contrast agents.  In this study, expression and Glutathione-S-
Transferase purification procedures were optimized, and a refolding method for rapid production 
of ProCA1 has been developed to enable studies of conformation, metal binding, relaxivity, and 
in vivo applications. Several ProCA1 variants with 4-5 charged ligand residues were shown to 
have strong gadolinium binding affinity (Kd of 10
-12 
M) and metal selectivity. Several options to 
improve ProCA1 have been explored, including addition of a polyethylene chain or a bombesin 
tag. 
INDEX WORDS:  Magnetic Resonance Imaging, Contrast agents, Relaxivity, Gadolinium, GST, 
Refolding method, PEGylation.
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CHAPTER 1: INTRODUCTION 
1.1 Principles of Magnetic Resonance Imaging   
Magnetic Resonance Imaging (MRI) is one of the most crucial techniques for medical 
diagnostic imaging because of its capability to provide high resolution images of soft tissues in 
vivo. MRI is noninvasive and uses no harmful radiation, and is therefore advantageous over other 
imaging techniques such as X-ray and positron emission tomography. MRI produces three 
dimensional images useful for diagnostics by recording discrepancies in relaxation time among 
neighboring, but physiologically different tissues [1; 2].        
 Magnetic resonance relies on the magnetic properties of the hydrogen atom, which 
possesses an one proton and has a nonzero spin. This allows hydrogen to interact with and be 
influenced by both external magnetic fields and radio waves. An MRI scan is able to detect 
signals from hydrogen atoms most abundantly found in the form of water molecules, unlike other 
compounds such as 
12
C, 
16
O, and 
14
N, which are also present in biological tissues, but are 
uninfluenced by MRI [3].  
The magnetic properties of hydrogen and other atoms are believed to originate from the 
spin properties of the nuclei, each characterized by a magnetic moment (µ) and angular 
momentum (J) related to mass and charge [4]. The magnetic moment describes how much torque 
an atom can exert on the external magnetic field (Figure 1.1 A), while the angular momentum 
arises from the spinning particles (Figure 1.1 B).   Equation 1.1, in which µ, τmax, and B0 
correspond to magnetic moment, torque, and magnetic field strength respectively, shows 
magnetic moment relationships [3]: 
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   µ = τmax / B0                            (Equation 1.1)                                                          
Equation 1.2, in which J, m, v and r correspond to the angular momentum, mass, velocity, and 
radius, shows the angular momentum relationship [3]: 
     J=mvr     (Equation 1.2) 
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Figure 1.1 The magnetic moment and the angular momentum for spinning protons (A) Shows 
the magnetic moment, µ. (B) Shows the angular momentum, J. Taken from [3]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) (B) 
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 Both the proton and neutron in hydrogen each have a spin of + ½ (magnetic quantum 
number); yet the proton has a charge while the neutron has none. When the number of protons 
equals the number of neutrons, as in most atoms, there is no net magnetization, because the 
protons and neutrons align in such a way that their spins and magnetizations cancel.  But in 
atoms such as 
1
H,
 
cancellation does not occur because the unpaired electron produces a 
constantly changing magnetic field around the atom, due to vibrational and rotational motions 
[5]. 
Normally, hydrogen has no net magnetization because the nuclei are in a low energy state 
with random orientation in the absence of a strong magnetic field (Figure 1.2 A).  However, 
hydrogen nuclei in water molecules will adopt a new axis of rotation that is either parallel or anti 
parallel to an applied external magnetic field (Figure 1.2 B).  
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Figure 1.2 Process of Relaxation. (A) Random alignment of hydrogen atoms in the absence of 
an applied magnetic field. (B) In the presence of an applied magnetic field, B0, hydrogen nuclei 
adopt a spin either parallel or anti parallel to B0. (C) When an RF pulse B0 is applied, the 
magnetic moment of the nuclei deviates away from B0, and (D) subsequently realigns with B0 
following removal of the RF pulse, causing the nuclei give off energy in the form of an RF 
signal. Taken from [6]. 
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If the sample is then subjected to a pulse of energy with high radiofrequency (RF) 
perpendicular to the direction of the magnetic field, it will absorb some of this energy, causing 
the magnetic moment to deviate from the magnetic field (Figure 1.2 C).  When the RF pulse is 
removed, the nuclei begin to precess, or rotate in a motion similar to “[tracing] the walls of a 
cone” (Figure 1.2 D). The effect of this motion is a release of energy (RF) from the sample as the 
atoms return from a high energy to a low energy state, the frequency of which is called the 
Larmor frequency (ν) [5].  
The Larmor frequency is directly proportional to the strength of the magnetic field B0  
multiplied by the gyromagnetic ratio γ (a nuclei- dependent constant) [5; 7; 8].    
    ν = γB0      (Equation 1.3)  
 The nuclei in a sample of 
1
H emit signals of identical frequency, thus the Larmor 
frequency is said to depend solely on the strength of the magnetic field. An MRI of a chosen 
magnetic field strength records the signal emitted as the sample “relaxes”, or returns to its initial 
orientation relative to the magnetic field. Among other atoms with unpaired  electrons such as 
13
C, 
19
F, 
23
Na, 
31
P, 
1
H is most frequently used in NMR because of its natural abundance, 
sensitivity, and high Gyromagnetic ratio compared with 
13
C and 
15
N [5; 7]. 
MRI measures the time it takes for the perturbed protons in a sample to reorient with the 
magnetic field, which varies by environment and tissue type. The process of proton relaxation 
occurs via two simultaneous mechanisms: spin-lattice (longitudinal) relaxation (r1) and spin-spin 
(transverse) relaxation (r2). The spin-lattice or longitudinal relaxation time (T1) describes the 
time it takes for a perturbed proton to return to its original orientation in the magnetic field. The 
environment in which the nuclei are in, or the lattice, interacts with these high energy nuclei and 
through vibrational and rational motions causes them to return to a low energy state. 
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Longitudinal relaxation for a precessing proton is illustrated in Figure 1.3A. The proton is 
observed to precess at an angle θ following the initial RF pulse. As the proton loses energy 
gained from the RF pulse, θ decreases and net magnetization realigns with the applied field (z-
axis). Equation 1.4 describes the time it takes for the magnetization (M) to decay; M0, t, and T1 
correspond to the initial magnetization, time, and longitudinal relaxation time, respectively [5].  
   M = M0 (1 – e
-t/T1
)      (Equation 1.4) 
At the same time the nuclei realign with the field, they all resume their natural tendency 
to spin, but the spinning quickly becomes out of phase. This occurs because although the atoms 
are precessing at the same frequency their quantum states are different [5]. Spin-spin relaxation 
time (T2), known as transverse relaxation time, measures the process of a nucleus going from a 
high to a low energy state,  which is a less prominent signal than the T1 signal.  Figure 1.3B 
shows that as the sample precesses, the magnetization vector begins to separate into vector 
components in the xy plane, or dephase. Finally the vectors cancel each other out in all directions 
as the spin-lattice relaxation also decreases. Equation 1.1.5 describes how the intensity (I) of the 
signal drops as dephasing occurs over time; I0, t, and T2 correspond to the initial intensity, time, 
and transverse relaxation time, respectively [5; 9].   
   I = I0 (1 – e 
–t/T2 
)       (Equation 1.5) 
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Figure 1.3 Diagrams illustrate simultaneous, but different processes of relaxivity (A) R1 
relaxivity (B) R2 relaxivity. Taken from [5]. 
(A) 
(B) 
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1.2 Contrast Agents are Needed to Overcome Low Sensitivity in MRI  
 One of the greatest limitations in MRI is low sensitivity. While MRI instruments are 
capable of attaining images, many rely on a contrast agent to enhance the image considerably 
and to increase the sensitivity and specificity of MRI [10]. Contrast agents are typically 
paramagnetic substances, which means they have unpaired electrons capable of being influenced 
by a magnetic field. A contrast agent is capable of catalytically increasing the relaxation rate of 
surrounding water molecules by decreasing T1 and T2, thereby increasing the degree of contrast 
on an image. This ability is called the “relaxivity,” r1 or r2, of a contrast agent. Relaxivity, or how 
well a contrast agent is able to change the proton relaxation at a 1 mM concentration, is a 
measure of the effectiveness of the contrast agent [10]; high-quality contrast agents with high 
relaxivity are able to reduce the signal to noise ratio considerably. 
  Among the lanthanides, gadolinium has seven unpaired electrons, a high magnetic 
moment, long electronic relaxation times, and is capable of exerting the strongest effect on T1 
[11]. Gadolinium-based contrast agents are typically small molecules that chelate gadolinium in 
order to avoid the toxic effects of free metal [1].  After the sample is treated with contrast agent, 
the relaxivity, relative to the concentration of contrast agent, is shown in Equation 1.6 (adapted 
from source [8]).    
    
(Equation 1.6) 
 There are two types of contrast agents; those that that lengthen the relaxation rate of T1, 
or T1-agents (brightening agents), and those that alter the relation rate of T2, or T2-agents 
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(darkening agents). The most common T1-agent is a gadolinium complex, capable of producing a 
positive contrast by reducing T1. T2-agents include iron-oxide agents capable of producing a 
negative contrast [10].  Typically, T1-agents are used because of its availability.  
1.3 Contrast Agent Relaxivity is Influenced by Several Parameters 
 Water molecules in the vicinity of gadolinium are affected by its paramagnetic influence. 
“The origin of relaxation is the dipole-dipole interactions between the proton nuclear spins and 
the fluctuating local magnetic field that results from the paramagnetic metal center” [10]. 
Components that make up the observed relaxivity originate from inner sphere and outer sphere 
relaxation (Figure 1.4). Protons directly coordinated with the gadolinium center contribute to 
inner sphere relaxation, while “bulk solvent water molecules” contribute to outer sphere 
relaxation [10].  Parameters that affect relaxation are water exchange rate (Kex or 1/τm), radial 
distance between protons and metal center, rotational diffusion (τR), hydration number of the 
spheres (q), and the electronic properties of the gadolinium ion (T1e). Water exchange between 
surrounding water molecules and coordinated water molecules must be a fast process for high 
relaxivity; molecular rotational correlation time must be slow; hydration number must be as high 
as possible without loss of affinity between gadolinium and its complex. Development of 
improved contrast agents can be achieved by manipulating these parameters, which are related 
by Equation 1.7, where 1/Tc1 is equal to the inverse Larmour frequency [10]: 
                  1/Tc1 = 1/ τR + 1/ T1e + 1/ τm          (Equation 1.7) 
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Figure 1.4 Cartoon illustration of parameters affecting inner and outer/second sphere relaxivity, 
including water exchange rate, molecular rotational correlation time, electronic relaxation time 
of gadolinium, and ionic distance between protons and gadolinium; sphere represents water 
molecule. Taken from [10].  
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Optimization of the water exchange rate, the molecular correlation time, and the hydration 
number of the inner sphere are ways to improve the effectiveness of contrast capability. 
1.4 Criteria for Design and Development of High-quality MRI Contrast Agents  
Current clinical agents are small molecules that chelate gadolinium, mostly 
polycarboxyamides. While they are easily synthesized, their reported relaxivities are 5 mM
-1
s
-1
 
and their effectiveness is noticeable only at high dosages, 300-500 mM. The retention time is 
short in tissues (less than 30 minutes). Additionally, the sensitivity is low and these agents 
cannot detect molecular biomarker expression. Therefore, repeated doses are needed to obtain a 
clear image. Because of their fast molecular correlation time of 100 ps and a slow inner sphere 
water exchange rate, the relaxivity of commercially used contrast agents, such as Magnevist, are 
said to be compromised, as the relaxivity falls short of the theoretically possible value of 100 
mM
-1
s
-1
.  Also, these contrast agents are considered blood pool agents which means they lack 
target specificity [1; 2]. In addition, recent concerns have arisen over the renal toxicity of these 
contrast agents, with increased incidences of nephrogenic systemic dermopathy (NSD) reported 
after a gadolinium MRI in patients with preexisting kidney conditions [12]. For these reasons 
there is a pressing need for a new type of contrast agent.  
A high-quality contrast agent is sought after, which will display high relaxivity, high affinity 
for lanthanides over physiological metals, in vivo stability, minimal toxicity, longer retention 
time in tissues for reduced dosage frequency and for sufficient imaging time, and a small-sized 
chelator for quick renal filtration from the body. Increasing the relaxivity is beneficial in 
reducing the dosage necessary to provide a high quality image, thus an increase in dosage 
efficiency. High affinity for lanthanides will prevent binding of physiological metals and prevent 
toxicity caused by free circulating gadolinium. In addition, they should have strong metal 
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selectivity over excess amounts of physiological metal ions such as calcium, zinc and 
magnesium. Lastly, they should be easily produced in large-scale amounts with minimal steps of 
preparation. 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 14 
 
 
 
 
 
Figure 1.5 Commercial contrast agents approved by the FDA include Magnevist, Dotarem, 
Omniscan, ProHance, Multi-Hance, and Gadovist. Taken from [13].  
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 As mentioned earlier, one approach to improving the relaxivity is to adjust the parameters 
that affect it. One parameter that has been addressed in recent research is reducing the fast 
molecular rotational correlation time of currently used contrast agents (Figure 1.6 i) [8]. The 
strategy is to covalently attach two chains of Gd-DTPA or Gd-DOTA molecules to larger 
macromolecules such as linear polymers, dendrimers, liposomes, viral capsids, or proteins. 
While these molecules in fact exhibit a larger molecular rotational correlation time, the relaxivity 
has not shown to increase appreciably compared to commercial contrast agents. This is because 
intrinsic internal mobility is high and the water exchange rate is restricted (Figure 1.6 ii). As a 
matter of fact, the size of these molecules, 10-100 nm, will further hinder proper filtration by the 
kidneys, an already existing toxicity concern with gadolinium contrast agents.   
 The strategy of designing a lanthanide binding site into a protein has been used in our 
laboratory to create a novel class of contrast agents (ProCA1) that addresses the limitations of 
current contrast agents. ProCA1 exhibits higher relaxivity, optimized pharmacokinetics and 
biodistribution, quick renal excretion, and lower dose efficiency. The protein provides a rigid 
binding framework with high affinity for gadolinium, and limitations such as internal mobility 
are eliminated; rotational correlation time is observed for the Gd
3+
-protein unit as a whole 
(Figure 1.6 iii) [1].  
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  . 
 
Figure 1.6 Representation of contrast agent models. (i) Small chelating molecules such as Gd-
DTPA with τR exceeding 100 ps. (ii) One or more Gd-DTPA or Gd-DOTA molecules covalently 
bound to a macromolecule still has fast τR due to internal mobility. (iii)  Protein with metal 
binding site provides rigid binding framework with high affinity for gadolinium, a slow τR 
observed for the Gd
3+
-protein unit as a whole. Taken from [1]. 
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1.5 Design of Protein-Based Contrast Agents  
1.5.1 Engineered Proteins and ProCA1 
Engineered proteins are gaining recognition for serving a broad range of interests in 
research, including elucidating the structure and function relationship of proteins, the 
development of analyte sensors, protein drugs, vaccines, and diagnostic probes. Dr. Jenny 
Yang’s laboratory has used a novel design approach to introduce a metal binding pocket in the 
first domain of scaffold protein, CD2.d1, through protein engineering. The result is a class of 
protein-based contrast agents (ProCA1) that have shown improved relaxivity over Gd-DTPA.  In 
contrast to commercial contrast agents a longer correlation time of 10 ns is observed in ProCA1 
rather than 100 ps, because of a larger molecular weight (11.2 kDa versus 743 Da in Gd-DTPA). 
Gd-ProCA1 has an r1 of 117 mM
-1
s
-1
 and an r2 of 129 mM
-1
s
-1
 compared with Gd-DTPA which 
has an r1 of 5.4 mM
-1
s
-1
 and an r2 of 8 mM
-1
s
-1
 in the same field strength (1.5 Tesla) (Figure 1.7 
A). A 40 fold lower dosage than Gd-DTPA is needed for enhancement of kidney images (Figure 
1.7 B). ProCAs also has a high metal binding affinity in the pM range, which decreases the risks 
of free metal toxicity associated with NSD.  The small size of  CD2.d1, 2 nm, allows for easy 
renal excretion and intravascular distribution [1].   
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(A) 
 
(B) 
 
 
Figure 1.7 (A) Relaxivity values of gadolinium-bound ProCA1 are significantly higher than 
relaxivity values of Gd-DTPA. (B) Injection of contrast agent injection into a 26 g mouse 
produce enhanced MR images of organs (arrows). The left side shows pre-injection, and the right 
side shows 40 minutes post injection of 50 μL of 1.2 mM Gd3+-CA1.CD2. Taken from [1].  
 
 
CA Class Compounds (ligand residues) r1 (mM
-1
s
-1
) r2 (mM
-1
s
-1
) B0 (T) 
Designed proteins Gd
3+
-CA.CD2 117 129 1.5 
  (E15/E56/D58/D62/D64) 48 88 3.0 
  
 
6 50 9.4 
Small compound Gd-DTPA 5.4 8 1.5 
    4.2 6.8 3.0 
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1.5.2 Choice of Protein Host 
Several different high coordination Ca
2+ 
/La
3+
 binding sites have been designed in domain 
1 of wild-type CD2 to understand key determinants for Ca
2+
 binding and Ca
2+
 dependent 
conformational change. CD2 is a cell adhesion molecule found on the surface of T-cells and 
natural killer cells and is part of the signal transduction pathway. It is composed of nine β-
strands, forming two layers that give rise to a typical immunoglobulin fold. Along with Ig 
domains, CD2 has a transmembrane region, and a short cytoplasmic tail involved in protein-
protein interactions (Figure 1.8) [14].  
CD2.d1 was chosen as a host because of its high stability over a range of pH values 2-10 
and salt concentrations 0-4 M. Additionally, it tolerates mutations for metal binding without 
significant change in globular structure, an important feature as a scaffold for contrast agents. 
CD2.d1 has two active tryptophan residues at positions 7 and 32, which can be used as 
spectroscopic probes for structure and metal binding studies using Tb
3+
-Tryptophan sensitive 
FRET. Extensive structural studies have been performed using NMR and x-ray (Figure 1.8).  
In the past, the Yang group has used two approaches to study calcium and lanthanide 
binding: the grafting approach, and the design approach. The grafting approach has allowed us to 
determine the calcium affinity to each of the four loops in calmodulin individually. The idea is to 
graft, or insert each of four calcium binding loops into CD2.d1, a rigid scaffold protein that does 
not bind calcium. This has allowed the determination of calcium binding affinity of each loop of 
calmodulin independently.  This approach has been used to design calcium sensors as well.  
The design approach allows the study of a single metal binding site in a host protein by 
directly mutating the residues within the protein. This eliminates the difficulties with multi-site 
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systems and metal-metal interaction, allowing us to understand the role of key factors such as net 
charge and ligand type on calcium binding affinity within a well-defined system.   
 The first domain of CD2 has been mutated using the design approach on the β-strand B to 
introduce a metal binding site formed by five coordinating ligands (E15, E56, D58, D62, D64). 
CD2.7E15, the novel protein, contains a class 2 calcium binding site with pentagonal 
bipyramidal arrangement of the ligands. CD2.7E15 differs from wild-type CD2 by 3 amino 
acids, utilizing 2 residues directly from CD2  [15]. Another mutant, CD2.6D31 has a calcium 
binding site formed by four coordinating ligand residues (E29, D31, D41, D43) (Figure 1.9).  
 Previous studies have shown that the two CD2 variants 7E15 and 6D31 exhibit different 
protein stability and conformational properties. The introduction of calcium ligand residues for 
7E15 was found to lower the melting temperature (Tm) from 61 °C (seen in the wildtype) to 
41°C, while retaining the wild type conformation in the presence and absence of Ca
2+
. On the 
other hand, CD2.6D31 is unfolded in the absence of calcium. It retains its native like 
conformation upon binding of calcium [16].  
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Figure 1.8 Rat cell adhesion protein CD2.d1 (1hng) is chosen as a host protein for protein-based 
contrast agent design. Two tryptophan residues at positions 7 and 32 are shown in red. 
 
Figure 1.9 Pymol illustration of design of wild-type CD2 variants. (A) CD2.6D31 showing 
structure of La
3+/
Ca
2+
 binding pocket formed by four coordinating ligand residues (E29, D31, 
D41, D43). (B) La
3+
/Ca
2+
 binding protein CD2.7E15 with five coordinating ligands (E15, E56, 
D58, D62, D64) (left) has pentagonal bipyramidal arrangement of the metal binding site (right). 
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1.5.3 Charged Variants of ProCA1 as Suitable Candidates for Contrast Agents  
Charged variants of ProCA1 (or 7E15) were created by Dr. Anna Wilkins Maniccia 
utilizing the design approach with site-directed mutagenesis [17]. One of the intentions of 
creating 7E15 charged variants was to study whether varying the charge or coordination residue 
type in the metal binding pocket would affect calcium binding compared to the template, 7E15, 
within a fixed binding site [15]. Drs. Anna Maniccia and Wei Yang have shown that calcium 
binding affinity is increased as the charge in the binding pocket is increased.  CD2.7E15 has a 
strong metal binding affinity for Tb
3+
 (Kd~10
-10
 M), as shown by FRET, and a weak calcium 
binding affinity (Kd of 0.15 mM). In later work, CD2.7E15 was shown to be an excellent MRI 
contrast agent with a strong Gd
3+
 binding affinity (Kd~10
-10
 M), as demonstrated with a metal 
buffer system, and significantly improved relaxivity [1]. 
It is not clear whether other charged variants are good candidates for MRI contrast 
agents. Among several available charged variants created, three -5 and -4 charged variants have a 
strong potential as MRI contrast agents. Residue 64 in 7E15 was changed to glutamate (called 
EEDDE in [15;17] or 7E15E throughout this paper) to create a -5 pair, 7E15/7E15E that differs 
by a methylene group. This residue was changed to glutamine or aspargine (called EEDDQ and 
EEDDN in [15;17] or 7E15Q and 7E15N throughout this paper), a -4 pair that also differs by a 
methylene group. One of the objectives of this thesis is to examine Tb
3+
, Gd
3+
, and Zn
2+
 binding 
with different charged variants and to examine the suitability of these proteins as the next 
contrast agents (Chapter 4).   
1.6 Expression Systems: Factors Affecting Protein Expression  
 Large-scale production of the engineered proteins is crucial for structural analysis, 
functional analysis, therapeutic and in vivo studies. It is essential for the project of protein-based 
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Magnetic Resonance Imaging contrast agent carried out in Dr. Yang’s laboratory. For example, 
an injection into a mouse for in vivo studies may require 5.6 mg of pure protein, and many metal 
binding titration experiments require up to 1 mL of highly concentrated protein (500 µM) for 
efficient trials.  The first step to increasing the production of proteins is optimizing the 
expression conditions, which is crucial for preventing aggregation, degradation, and improper 
folding commonly seen in recombinant proteins.  
 Protein expression is highly dependent on the cell strain and conditions such as 
temperature, vector, medium, and the protein of interest. Bacterial strains versus mammalian 
have been shown to tolerate recombinant protein and to synthesize and fold protein well. 
Bacterial expression may result in well folded protein or an inclusion body depending on the 
expression levels. At high temperatures, E. coli tends to replicate quickly, producing more 
protein than the bacterial cells can fold at once.  Under these conditions, high energy polypeptide 
intermediates will interact in a hydrophobic manner, thus aggregating to form a dense inclusion 
body.  This dense structure of improperly folded, unprocessed protein will be more likely to form 
at higher temperatures, depending on cell strain and protein.  
The expression vector contains a promoter site for expression that can affect the 
efficiency of expression. The pGEX-2T vector is designed to contain a GST tag attached near the 
N-terminal of the target protein through a short peptide chain for specific endoprotease cleavage 
[18]. Both pGEX-2T and pET-20b vectors contain a T7 promoter system, which is similar to the 
lac operon in E. coli (Figure 1.10). Depending on the cell strain, the promoter may be IPTG- 
sensitive. The vector pGEX-2T contains a GST tag which binds to the affinity column for 
purification and increases the solubility of the protein, while pET-20b does not [19]. 
Additionally, protein expression level and folding is a property of the fusion protein of interest. 
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Figure 1.10 Novagen expression vectors pGEX-2T and pET-20b; pGEX-2T contains a  
GST purification tag while pET20b does not. Taken from [20; 21].  
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1.7 Purification Systems 
 1.7.1 Comparison of Affinity Tag Purification Systems 
To achieve rapid expression and maximum purification of the recombinant proteins, 
affinity tags have been developed to fuse with proteins. Different models have been developed to 
incorporate tags. In the first model, a native protein is linked with an affinity tag by a linker 
region that has a sequence for endoprotease cleavage by thrombin. The second model is similar 
to the first except the affinity tag increases the overall solubility of the protein. Examples include 
Glutathione-S-Transferase (GST) and Maltose Binding Protein. In the third model, a fusion 
protein consists of an affinity tag removable by exopeptidase activity.  In the fourth model the 
native protein is bound to a solubility and folding partner, fused N-Terminal to the target protein 
[22]. 
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Figure 1.11 Models to incorporate affinity tags to target proteins. (1)  Fusion protein containing 
native protein attached to an affinity tag via a linker region which has a sequence for 
endoprotease cleavage. (2) In this model the affinity tag enhances the solubility of the protein 
(examples are GST, MBP). (3) Fusion protein with exopeptidase removal of affinity tag. (4) 
Fusion protein where a solubility and folding region is placed between the native protein and 
affinity tag. Taken from [22]. 
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Several affinity tags have been developed according to the above models including 
Maltose Binding Protein (MBP), Calmodulin Binding Peptide (CBP), Glutathione-S-Transferase 
(GST), Histidine (His), and FLAG. Use of MBP or CBP is based on affinity amylase or 
calmodulin, respectively, which are placed on chromatography resins. His tag is a sequence of 6 
histidine residues (vector pET30a) that can bind nickel resins via high affinity of imidazole to 
nickel; His tags have known to improve folding of protein. GST is an enzyme that binds 
glutathione on affinity columns; GST tags have been used to increase solubility of small proteins 
expressed in E.coli [22, 18]. FLAG fusion protein is purified via anti-FLAG antibody binding to 
the FLAG sequence. GST and His tags are top choices for large scale expression and purification 
due to high capacity and low cost (Table 1.1) [22].  
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Table 1.1 Comparison of affinity tags contrasting capacity and cost to obtain 10 mg  
pure protein shows His and GST tags are top choices for large scale production of  
recombinant proteins. Taken from [18]. 
              
Tag Size (aa) Resin Eluting agent Source Capacity Cost/10 mg 
MBP 396 Amylose Maltose Biolabs 3 mg/ml $12 
HIS 6 Talon Imidazole Clontech 5–14 mg/ml $18 
  
Ni–NTA Imidazole Qiagen 5–10 mg/ml $21 
GST 218 GSH–Sepharose Glutathione Amersham 10 mg/ml $36 
CBP 28 Calmodulin affinity EGTA Stratagene 2 mg/ml $114 
STR (Strep II) 8 Strep-Tactin–Sepharose Desthiobiotin IBA 50–100 nmol/ml $293 
FLAG 8 
Anti-FLAG M2 MAb 
agarose FLAG peptide Sigma 0.6 mg/ml $1,045 
HPC 12 Anti-Protein C MAb matrix EDTA Roche 2–10 nmol/ml $4,983 
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1.7.2 Problems with GST Purification  
In many cases, high expression level of GST fusion proteins is evident, while low yield is 
seen following purification (2-5 mg/ L cell culture). After sonication, protein in the supernatant 
does not bind well to the GST column, and a large portion is found in the waste. There is reason 
to believe that some or most of the protein expressed may be misfolded or denatured, rendering it 
unable to bind to affinity columns. Low yield of purification despite high expression is thought 
to occur due to problems during expression, such aggregation, degradation, and improper folding 
of fusion proteins (Figure 1.12).  
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Figure 1.12 Expression and purification of GST fusion protein. (A) Shows high yield following 
expression 5 hours after induction with IPTG. (B) Following purification, a large amount of 
fusion proteins does not bind to GST beads and passes through the columns (in WST) and a low 
yield is seen at the fraction which eluted with glutathione.  
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1.7.3 Method of Refolding the Expressed Protein without Affinity Tag 
 While considerable effort was devoted to optimizing GST purification, the option of 
refolding of CD2.7E15 expressed as inclusion body without GST tag was investigated as a 
possibility to increase protein yield. The premise of these studies is that domain 1 of CD2 has 
shown to have a stable IgG-like fold and can be refolded well [23]; CD2.7E15 differs from its 
parent protein by 3 mutations and is likely to behave similarly.  
Over-expression in E.coli in general has been shown to maximize the production of 
protein. As well, it was found from the GST studies that CD2.7E15 has a propensity to form high 
amounts of inclusion bodies under specific expression conditions which consists mostly of 
protein. The advantage of forming an inclusion body is protection from protease degradation, 
which would be likely because of protein size (11 kDa).  
 Additionally, several disadvantages of using GST tags have driven the search for this 
novel purification method. The use of thrombin during purification to cleave the Arg-Gly bond 
between GST and CD2.7E15 is not only expensive, but also reduces the yield of protein and 
results in excess cleaving [24]. Also the size of GST (26 kDa) compared to CD2.7E15 results in 
E. coli resources to be directed mostly at GST.  Furthermore, previous studies have indicated a 
drastic increase in yield of His-Tag-7E15 proteins (166 mg/ L cell culture) using the refolding 
method (Julian Johnson, unpublished data).         
 
 
 
 
 
 32 
 
 
 
 
 
 
 
Figure 1.13 Schematic of refolding method. 
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1.8 Objectives of Thesis 
 As discussed in section 1.4, scaled up production of the CD2.7E15 and CD2.7E15 
charged variants will provide a sufficient amount of protein necessary for structural and 
functional analysis, as well as therapeutic and in vivo studies, the first steps of studying these 
proteins as future clinical contrast agents. The objective of this thesis is to examine expression 
and purification conditions that will maximize the production of these contrast agents, then to 
determine suitability of engineered proteins as contrast agents via structural, metal binding, and 
relaxivity studies.  
In the effort to obtain engineered proteins for biochemical and structural study and in vivo 
application, the proteins wild type CD2, CD2.7E15, CD2.6D31 were expressed as a fusion 
protein with the Glutathione-S-Transferase affinity tag under three different temperatures and 
three different cell strains, and were purified based on affinity column chromatography.  The 
objective is to determine the optimal conditions for expression and GST purification (chapter 2). 
Then, CD2.7E15 expressed with a His tag and without a tag will be used to study the 
effectiveness of purification via the refolding method. A tag-less purification protocol is 
established as the most efficient purification method and is used thereon to purify all proteins 
(chapter 3). High purification yield is obtained using the refolding method, and CD2.7E15 and 
charged variants are studied as suitable contrast agents, using conformational and metal binding 
studies as well as relaxivity (chapter 4).  Insertion of a PEG chains or peptide tags (bombesin) on 
various sites on ProCA1 are studied as possible ways to enhance protein-based contrast agents 
(chapter 5).  Table 1.2 summarizes all the proteins studied in this thesis and their purpose.     
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Protein Variation Purpose of variation Chapter(s) discussed  
 
CD2.7E15/7E15 
3 mutations of wild-
type CD2 residues 
N15, L58, and K64 to 
E15, D58, and D64 
To create a -5 charged 
binding pocket for the 
study of metal binding 
as contrast agents 
 
2,3,4 
 
CD2.6D31 
2 mutations of wild-
type CD2 residues 
R31 and K43, to D31 
and D43 
To create a -4 charged 
binding pocket for the 
study of metal binding 
as contrast agents 
 
2 
 
CD2.7E15E 
1 mutation of 
CD2.7E15 from 
residue D64 to E64 
To create a -5 charged 
analogue of 
CD2.7E15 for the 
study of metal binding 
 
 
 
 
CD2.7E15N 
 
 
1 mutation of 
CD2.7E15 from 
residue D64 to N64 
 
 
 
To create a -4 charged 
analogue of 
CD2.7E15 for the 
study of metal binding 
 
 
4 
 
CD2.7E15Q 
1 mutation of 
CD2.7E15 from 
residue D64 to Q64 
  
 
Table 1. 2 Summarizes proteins generated for projects throughout this thesis and their variations, 
the purpose of their variations, and the chapters in which they are discussed. 
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Protein Variation Purpose of variation Chapter(s) discussed  
 
 
 
K3CR 
3 lysine resides from 
the C terminal are 
mutated to arginines 
(K51, K66, K91R), 
and the remaining 
lysine residues are 
PEGylated (K43, 
K45, K47). 
  
 
 
 
K5R 
5 lysine resides are 
mutated to arginines 
(K43, K47, K51, K66, 
K91R), and the 
remaining lysine 
residues are 
PEGylated (K45). 
 
 
 
To test the effect of 
PEGylation in 
multiple locations 
near the binding site 
on relaxivity. 
 
 
 
 
K5166R 
2 lysine resides are 
mutated to arginines 
(K51 and K66), and 
the remaining lysine 
residues are 
PEGylated (K43, 
K45, K47k and K91). 
  
 
 
5 
 
 
 
K6691R 
2 lysine resides are 
mutated to arginines 
(K66 and K91), and 
the remaining lysine 
residues are 
PEGylated (K43, 
K45, K47 and K51). 
  
 
 
 
K51C 
 
 
1 lysine residue (K51) 
is mutated to cysteine 
and is PEGylated by a 
cysteine reagent. 
 
 
 
To test the effect of 
PEGylation in a single 
location near the 
binding site on 
relaxivity. 
 
 
 
K66C 
1 lysine residue (K66) 
is mutated to cysteine 
and is PEGylated by a 
cysteine reagent. 
  
 
Table 1.2 (continued).  
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CHAPTER 2: OPTIMAL CONDITIONS FOR GST TAG EXPRESSION AND 
PURIFICATION 
2.1 Background about GST and Affinity Tag in Protein Purification 
As discussed in section 1.7.1, the use of affinity tags such as GST is an effective choice 
to mass produce recombinant proteins because of high levels of expression and enhanced 
solubility of the fusion protein in the cytoplasm. However, as pointed out in section 1.7.2, high 
expression of fusion protein is not a guarantee that high yield is achieved. Some or most of the 
protein is believed to aggregate in the cytoplasm as inclusion bodies. It is believed that 
expression levels of soluble protein are dependent on conditions such as temperature and cell 
strain. Studies by Waldo et al with green fluorescent proteins (GFP) illustrate that properties of 
the N-terminal fusion tag will affect the folding of GFP, which serves as a folding reporter [25]. 
The opposite effect, where the influence of engineered protein on the folding of the N-terminal 
protein, has never been examined. In past studies, varying the expression conditions such as 
temperature or cell strain has had a direct influence over the levels of soluble versus insoluble 
CD2.7E15 produced. We hypothesize that controlling the expression conditions, or providing 
favorable expression conditions to obtain properly folded CD2.7E15, will influence the folding 
of its fusion partner, GST. Proper folding of GST is essential to maximizing the outcome during 
purification.   
In this study, we have chosen two engineered calcium binding proteins of CD2 with 
different folding properties as a fusion protein to test this hypothesis. We have investigated the 
expression of these CD2 variants and wild type under different temperatures and cell lines. 
Examination of SDS-PAGE, and BCA protein assay, is performed to monitor the cell growth and 
the expression ratio of soluble and insoluble proteins. This study examines the propensity of 
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inclusion body formation at three common expression temperatures: 37°C, 30°C, 25°C. 
Additionally, the binding capacity and ratio of soluble and insoluble protein is determined. 
 The GST enzymatic activity is monitored using the DTNB assay. GST enzyme exists as 
a dimer found in eukaryotes; each monomer is 26 kDa.  The active site of GST contains a G and 
H site for Glutathione and electrophilic substrates respectively, which has an active cysteine 
residue at position 10. This special cysteine forms covalent disulfide bonds with the thiol group 
of the substrate glutathione, and foreign matter in the cell.  The GST assay is reliant on the fact 
that GST joins CDNB and Glutathione in the active site and can be used to assess activity of the 
enzyme from different expression conditions.  The binding capability of these fusion proteins to 
affinity columns is examined and was found to correlate with the GST assay.    
For efficient binding to the Glutathione-S-Sepharose 4B affinity column, the GST tag on 
the fusion protein must be well-folded with its thiol group (on cysteine 10) positioned correctly.  
Unfortunately, in many cases, despite of high expression level of the fusion proteins, low yield of 
purification was reached largely due to the problems related to improper folding of engineered 
proteins as well as GST-tag.  
 
 38 
 
 
 
Figure 2. 1 Glutathione-S-Transferase enzyme exists as a dimer found in eukaryotes, and each 
monomer is 26 k Da.  The active site of GST (enlarged) contains an active cysteine residue at 
position 10. For efficient binding to the Glutathione-S-Sepharose 4B affinity column, the GST 
tag on the fusion protein must be well-folded with its thiol group (on cysteine 10) positioned 
correctly. 
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The results indicate that GST binding capability for protein purification is largely 
dependent on the folding properties of the fusion protein. When expressed under defined, 
optimal conditions, well-folded native protein was found to promote a proper conformation in 
the fusion partner, GST, whose folding and activity are keys to a high purification yield.  
2.2 Materials and Methods   
2.2.1 Cloning 
Cloning was conducted following established methods for GST-fusion proteins [26; 27].  
2.2.2 Transformation  
E. coli strains BL21 (DE3), Rosetta PLysS, and Tuner (Strategene, La Jolla, CA) were 
used for expression of proteins CD2.7E15, CD2.6D31, and wild type CD2. The vector plasmid 
pGEX-2T (GE healthcare) was used, which was designed to contain a Glutathione-S-Transferase 
(GST) tag DNAs. Domain 1 of CD2 and its variants DNAs were inserted into the vector as a 
GST fusion protein with a GST enzyme attached near the N-terminal of the protein through a 
short peptide chain that has a cleavage site for thrombin.   
Heat shock transformation was utilized to uptake the vectors containing the engineered 
DNA into E. coli cells. First, 0.75 µL of DNA was combined with 50 µL of competent cells, and 
the solution was iced for 30 minutes to allow diffusion of DNA through the 20% glycerol 
solution bathing competent cells. Next, the mixture was dropped in a 42  °C water bath for 
precisely 90 seconds to allow DNA uptake by the competent cells. The cells were then promptly 
returned to the ice bucket for 2 minutes, after which they were given 75 µL LB medium and 
incubated for 30 minutes at 37 °C. The cells were then streaked with a sterile triangle onto an 
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agar plate containing ampicillin and were allowed to incubate overnight at 37 °C, upside down. 
An additional plate containing cells without DNA was incubated as a negative control.  
2.2.3 Expression of Wild-type CD2, CD2.7E15, and CD2.6D31 GST Fusion Proteins 
A bacterial colony was inoculated and incubated overnight in LB medium with ampicillin 
(2.5 mM). The cell pellets were collected by centrifugation (Sorvall RC SB Plus Centrifuge, 
ThermoScientific, Bruswick, NJ) at 4.410 x 10
3
 g in 5 °C for 15 minutes. The cell pellets were 
diluted 1:20 with LB medium with ampicillin (2.5 mM), and were incubated at 37 °C in a shaker 
(Shaker Controlled Environment Incubator). 
The optical density (OD) of each sample at 600 nm was recorded every 30 minutes using 
a UV spectrophotometer (Shimadzu Scientific Instruments, Norcross, GA). When the OD 
reached 0.6 for BL21 (DE3) and Rosetta PLysS, and 0.5 for Tuner cells, Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to the cultures. The BL21 (DE3) and Rosetta pLysS 
strains required only 0.25 mM IPTG, while the Tuner strain required 0.5 mM. The shakers were 
adjusted to the desired temperature either 37°C, 30°C, or 25°C, for the duration of expression. 
The cell pellets were collected by centrifugation at 3.842 x 10
3
 g for 20 minutes after the cultures 
grew about 5 hours. The cell pellets were stored at -20 °C until purification. KaleidaGraph 
software (Synergy Software, Reading, PA) was used to plot the optical density versus time plots. 
Image J software (Version 1.37) was used to quantify band thickness as a result of expression on 
the 15% acrylamide SDS-PAGE gels. 
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Figure 2.2 Summary of expression procedure.  
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2.2.4 Purification of GST Fusion Proteins by Affinity Chromatography 
Cell pellet containing expressed protein was prepared by resuspension in 5 mL of lysis 
buffer (1% N-lauroylsarcosine sodium Tris-HCl, pH 7.0, 5 mM DTT, 5 M AEBSF, and 25 
U/mL benzonase nuclease (Novagen)). The mixture was sonicated six times at intervals of 30 
seconds each, and centrifuged to separate debris at 4.410 x 10
3
 g for 5 min. The supernatant was 
retained and filtered with a 0.45 µM filter. 
Glutathione-S-Sepharose 4B affinity columns (GE healthcare) with capacity of 2 mg/ 
1mL of resin, were treated with 9 M glutathione (GSH) for cleansing and rinsed with phosphate 
buffered saline (PBS). 
 The filtered supernatant was applied to affinity columns three times for binding to occur 
between the GST tag and the beads. In order to cleave the GST tag from the protein, 20 U of 
thrombin (GE healthcare) is added to each column, which is then placed on an agitator at room 
temperature for four hours. The target protein was eluted from the column with PBS buffer, 
followed by filtration with a 0.45 µM filter. In some case, the thrombin was not added to the 
affinity resin and the GST tag was not cleaved from the fusion protein. Once the fusion protein 
was bound to the column, the whole unit was eluted with highly concentrated glutathione by 
competition.     
Protein was then further purified by Superdex G75 gel filtration and HiTrap SP cation 
exchange FPLC (GE healthcare). 
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2.2.5 Bradford Concentration Assay (BCA) and GST Enzymatic Activity Assay  
 The BCA Protein Assay Kit (Thermo Scientific, Lot Number JD 121926) was used in 
order to quantify the ratio of soluble and insoluble protein in solution in accordance with the 
protocol.  
To examine the native folding of GST, we have monitored the GST activity using the 
GST Detection Module as detailed in the protocol (Amersham Biosciences, GE Healthcare). The 
GST activity assay is reliant on the fact that the GST enzyme binds glutathione and the 
electrophilic substrate Chloro-dinitrobenzene (CDNB) [28]. When fully oxidized GSH donates 
electrons to electrophilic CDNB, the absorbance at 340 nm increases. This assay measured the 
absorbance at 340 nm after GSH and CDNB were added to protein solution. The absorbance 
over the initial 100 seconds was observed, and over 20 points were plotted and fitted. The 
absorbance did not exceed 0.8. A negative control with buffer only was checked first to verify 
the absence of activity. The activity of GST, or the initial velocity, was found by calculating the 
slope of product concentration [P] (Equation 2.1) over time, where ε is the molar absorptivity, 
and l is the path length. 
[P] = A340nm/(ε * l)     (Equation 2.1) 
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Figure 2.3 GST Detection Module (GE healthcare) [29]. 
 
 
 
 
 
 
 
 
Reaction buffer: 1 M KH2PO4 pH= 6.5
Km (Glutathione): 0.43 + 0.07 mM
Km (CDNB): 2.63 + 0.77 mM
Monitor
Absorbance at 
340nm
+
100 mM CDNB
100 mM GSH
1 g cell pellet in
6 ml lysis buffer
sonicated
S-(2,4 dinitrophenyl) glutathione
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2.2.6 GST Beads Binding Assay  
 The GST beads binding assay was performed by mixing a 2:1 ratio of Glutathione-S-
Sepharose 4B beads with sample. Samples of the beads were drawn after the beads were bound 
with the protein and washed with phosphate saline buffer. Further analysis by an SDS-PAGE gel 
and Image J software provided a measure of the bead capacity by a comparison of the band 
intensity ratios. 
2.2.7 SDS-PAGE 
Prior to induction and hourly post induction, 1 mL samples were collected from the 
expression flasks for SDS-PAGE. As well, samples of the supernatant and cell pellet post 
sonication, and the beads before and after binding were collected for SDS-PAGE. All samples 
were centrifuged at 9.757x 10
3
 g for 1 minute in an eppendorf centrifuge and the supernatant was 
discarded. To each sample, a 1:10 ratio of SDS-PAGE sample buffer comprised of 5% ß-
mercaptoethanol was added. Samples were boiled at 100 °C for 10 minutes in a water bath. 
2.3 Results and Discussion 
2.3.1 Expression of CD2.7E15, CD2.6D31, and Wild-type CD2 
2.3.1.1 The Effect of Temperature on Protein Expression 
 The expression of wild-type CD2 and two variants at three different temperatures and 
cell strains five hours after induction with appropriate levels of IPTG is seen in Figure 2.3. 
CD2.7E15 was expressed efficiently at 25 °C or 30 °C, as shown by the intensity of the SDS-
PAGE. Expressions at 30 °C resulted in bands that were denser by 8-10% compared to 37°C.  At 
higher temperatures, cleavage of fusion protein is seen. Usually, the SDS-PAGE depicts two 
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bands for the expressed fusion protein, one of which is lower than 34 k Da.  The cleavage seems 
to diminish as the temperature is lowered (Figure 2.3 A, B and C).  
 SDS-PAGE depicting the expression of CD2.6D31 shows bands that were not 
significantly diverse from each other. The difference in density among the three temperatures did 
not exceed 4%. The same cleavage of fusion protein during expression was noted with higher 
temperatures, and band density decreased with temperature (Figure 2.3 D, E and F).   
 Wild-type CD2 was expressed in higher levels at 37 °C versus 25 °C. The SDS-PAGE 
shows bands that are darker at 37 °C by 4-9%, depending on the cell strain, that indicate the 
presence of the fusion protein (Figure 2.3 G, H and I).    
2.3.1.2 The Effect of Cell Strain on Expression 
 The three commonly used cell strains of Tuner, BL21 (DE3), and Rosetta pLysS, were 
tested for optimal expression. Although CD2.7E15 expressed in Tuner cells produced the densest 
bands on the SDS-PAGE, cleavage of the affinity tag was observed more than in other cell 
strains.  BL21 (DE3) and Rosetta pLysS produced the expression with the lowest amount of 
fusion protein cleavage. CD2.6D31 and wild-type CD2 produced the densest bands with Rosetta 
pLysS or BL21 (DE3) cell strains (Figure 2.3)  
 The difference in expression was apparent among the three fusion proteins. CD2.7E15 
expressed in higher amounts than wild-type CD2 and CD2.6D31 in all cell strains. In fact, SDS-
PAGE shows band densities of CD2.7E15 greater than wild-type CD2 by 10.6%, and CD2.6D31 
by 22.8%. Overall, CD2.6D31 expressed in the lowest amount among the three fusion proteins, 
followed by wild-type CD2, and CD2.7E15. 
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Figure 2.4 Expression gels showing the final point 5 hours after induction for each cell strain 
and temperature, growth curves, and wet cell pellet weights per 2 L expressed cell culture for 
CD2.7E15, CD2.6D31, and wild-type CD2. (A) Expression gel for CD2.7E15 shows that lower 
temperatures (25 °C or 30 °C) may be more effective for expression as bands are thicker by 8-
10%. (B) Growth curve for CD2.7E15 shows a gradual, steady growth for all cell strains. (C) 
Wet cell pellet weights is highest at 37 °C especially for Tuner cell strain. (D) Expression gel for 
CD2.6D31 shows no significant thickness among bands (less than 4% difference) but a more 
efficient growth with Rosetta pLysS. (E) Growth curve for CD2.6D31 shows a gradual, steady 
growth for all cell strains especially Rosetta pLysS. (F) Highest weight for cell pellet is seen at 
30°C. (G) Expression gel for wild-type CD2 shows thicker bands at 37 °C by 4-9%. (H) Growth 
curve for wild-type CD2 shows a gradual, steady growth for all cell strains especially. (I) Cell 
pellet weights are highest at 37 °C excluding Rosetta pLysS.  
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2.3.2 Estimation of Insoluble and Soluble Protein Ratio of Expressed Proteins by BCA 
Assay 
 The relative fractions of expressed fusion proteins as a soluble form or as an insoluble 
form in inclusion body were examined by measuring protein concentrations of 1 g cell pellets 
dissolved in lysate buffer or in the cell pellets using BCA protein assay (as described in section 
2.2.5).  Figure 2.4 shows that expression of CD2.7E15 at 37 °C tends to favor the production of 
inclusion bodies by approximately 10-40% more than expression of this protein at 30 °C or 
25°C. CD2.7E15 contains the highest level of inclusion bodies at 37 °C due to its especially high 
expression level in at this temperature. In CD2.6D31 expression, Tuner cell strain tends to 
produce the largest amounts of inclusion bodies, 10-20% more than in other cell strains. For this 
protein, Rosetta pLysS cell strain tends to produce less cell pellet. In wild-type CD2, the 
differences in inclusion body production across temperatures and cell strains were not as 
pronounced, none exceeding over a 10% difference. Decreasing expression temperature to 25 °C 
results in more soluble form of expressed proteins especially for CD2.7E15 and CD2.6D31. 
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Figure 2.5 Estimation of 
inclusion bodies in 1 g cell 
culture among wild type 
CD2 and two variants at 
expression temperatures 37 
°C, 30 °C, and 25 °C with 
cell strains Tuner, Rosetta 
pLysS, and BL21 (DE3). 
(A) Shows CD2.7E15 
inclusion body level is 
highest at 37 °C expression 
by approximately 10-40% 
more than in expression at 
30 °C or 25 °C. (B) Shows 
CD2.6D31 inclusion body 
level is 10-20% higher with 
use of Tuner than with use 
of Rosetta pLysS cell strain. 
(C)  In wild-type CD2, the 
differences in inclusion 
body production across 
temperatures and cell 
strains did not exceed 10%.
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2.3.3 The Relationship Between the GST Enzymatic Activity and Beads Binding Capability 
of the GST Fusion Protein  
In this study, the folding of GST is examined by measuring the enzymatic activity of the 
GST using the GST Enzymatic Assay (as detailed in section 2.2.6). Well-folded GST, which 
exhibited high activity in this assay, was found to bind to Glutathione-S-Sepharose 4B beads 
most efficiently.  
CD2.7E15 expressed at lower temperatures was found to have the highest enzymatic 
activity indicated by the fastest initial velocity (mM
-1
s
-1
) (Figure 2.5 A). Cell strains like Tuner 
seemed to express the most highly active GST, as well as BL21 (DE3) at 25 ºC. The SDS-PAGE 
of beads binding assay shows thick bands at the low temperature end up to 80% higher than the 
high temperature end, which means that the most active GST bound most efficiently to the 
affinity beads (Figure 2.7 A, B).  
Expression of CD2.6D31 specifically with the cell strain Rosetta pLysS regardless of 
temperature produced the most highly active GST (Figure 2.5 B). The SDS-PAGE gel depicting 
the beads binding assay correlates with the enzymatic activity: the most protein bound to the 
beads came mostly from the Rosetta pLysS samples (Figure 2.7 C and D). This was seen for all 
temperatures of expression especially at 30 ºC.  
 Figure 2.5 C shows that for wild-type CD2 expressed at 37 ºC, highly active protein was 
produced in cell lines like Tuner and BL21 (DE3).  Such protein bound to the beads in greatest 
amounts, as seen on the SDS-PAGE (Figure 2.7 E and F). Protein expressed at 30 ºC with 
Rosetta pLysS cell strain was also found to have the highest activity. The highest intensity bands 
were seen at high expression temperatures, which were thicker by approximately up to 70%.  
Wild-type CD2 was found to expresses highly active protein at temperatures of 37 ºC across all 
cell strains. 
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Figure 2. 6 Shows 
concentration of CDNB-
Glutathione (product) 
formation over time for the 
first 100 seconds plotted 
and fitted linearly. (A) 
CD2.7E15. (B) CD2.6D31. 
(C) CD2WT. The slope is 
equal to the initial velocity 
(V0).
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Figure 2.7 The initial 
velocity (V0) of GST fusion 
protein calculated from the 
slope of the graph of product 
concentration (mM) versus 
time (s) (Figure 2.6).  (A) 
Shows that enzymatic 
activity is highest for 
CD2.7E15 expressed at low 
temperatures. (B) Show that 
enzymatic activity is highest 
for CD2.6D31 expressed 
with Rosetta pLysS cell 
strain regardless of the 
temperature. (C) Shows that 
enzymatic activity is highest 
for wild-type CD2 expressed 
at 37 ºC regardless of the 
cell strain. Error bars refer to 
average standard deviation 
from three separate trials. 
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Figure 2.8 Beads binding capability assay of GST fusion protein monitored by SDS-PAGE (left) 
and intensity ratio (right) indicating binding capability is shown to correspond with the GST 
enzymatic activity. (A and B) In CD2.7E15 the high intensity bands from protein expressed at 
lower temperatures are thicker than the higher temperatures by up to 80%. (C and D) For 
CD2.6D31, the highest intensity bands came from proteins expressed with Rosetta pLysS cell 
strain. (E and F) In wild-type CD2, the highest intensity bands were seen at high temperature 
expression, which were thicker by approximately up to 70%.      
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2.4 Conclusions  
Optimal conditions were determined for the expression of each CD2 variant. Cell growth 
was found to be optimal at 37 °C for all three cell strains, as the replication of E. coli is maximal. 
Yet, the quantity of soluble protein produced during expression is variable, depending on the 
temperature and cell strain. CD2.7E15 was found to express the highest quantity of soluble, active 
protein at low temperatures with cell strain BL21 (DE3). Tuner was found to form high amounts 
of inclusion bodies in this protein. The optimal level of soluble and active CD2.6D31 was 
expressed with Rosetta pLysS, regardless of chosen temperature. Wild type CD2 was expressed in 
highest quantities of soluble form at higher temperatures, such as 37ºC. Cell strain preference for 
this protein was BL21 (DE3) and Tuner.  Overall, Tuner cell strain was found to produce the 
highest level of inclusion bodies for CD2.7E15 and CD2.6D31, and to cleave the fusion protein at 
37 ºC and 30 ºC. 
 The folding of the GST-affinity is largely dependent on the engineered protein folding. 
Ultimately, engineered protein folding is affected by the expression temperature and cell strain. 
Purification was carried out successfully, and correlations between beads binding assay and GST 
enzymatic activity indicate that high enzymatic activity in GST resulted in larger quantity of 
fusion protein binding to the affinity columns. CD2.7E15 expressed at low temperatures and in 
BL21 (DE3) is well folded, and thus the affinity tag is well folded and biologically functional. 
The same is true for CD2.6D31 and for wide type CD2 that are expressed in the optical conditions 
mentioned (Table 2.1). On the whole, purification level is highly linked with GST folding, which 
is tied back to the expression conditions. This information is a powerful tool for future work with 
these proteins. As seen in chapter 3, the tag-less purification method was optimized based on 
these findings.  
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Table 2.1 Summary showing the expression temperature and cell strain required to produce 
soluble fusion protein for wild-type CD2 and its variants.    
 
* Wild-type CD2 is soluble under these conditions, but the yield is low 
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CHAPTER 3: OPTIMIZATION OF A TAG-LESS PURIFICATION PROCEDURE TO 
IMPROVE THE YIELD OF ENGINEERED PROTEIN 
3.1 Introduction  
 The focus of chapter 2 was to optimize expression and purification of engineered protein 
using the GST system. Although this was performed successfully, the section 1.7.2 above had 
briefly mentioned the limitations of this method, and section 1.7.3 detailed that purification using 
a refolding method has shown increased yield in 7E15 and His-tagged 7E15. The refolding 
method is not effective with GST-tagged proteins because of the size of GST and the cysteine 
content. The need to establish a rapid method that would generate high yield of engineered 
protein for future study is addressed in this chapter. As mentioned in section 1.8, the purpose of 
this chapter is to detail the expression and purification experiments that led up to the 
establishment of the refolding method implemented in future chapters. Expression conditions 
found in chapter 2 to generate insoluble protein were used to generate inclusion bodies which 
were then refolded (Table 3.1). The objective is to use the refolding method to generate high 
yield of 7E15.   
Table 3.1 Summary of conditions found in chapter 2 with an added emphasis on conditions for 
inclusion body formation. 
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3.2  Materials and Methods   
3.2.1 Cloning  
 Cloning of 7E15 and 7E15-bom was performed by Lixia Wei  (Dr. Zhi-Ren Liu’s 
laboratory). Protein sequence was removed by restriction enzymes from the pGEX-2T vector and 
inserted into a pET30a vector, which contains a 6-histidine purification tag, between BamH1 and 
EcoR1 restriction sites.    
3.2.2 Transformation  
E.coli strains BL21 (DE3), BL21, BL21 (DE3) pLysS, and Tuner (Strategene, La Jolla, 
CA) were used for expression of proteins 7E15, His-7E15-bom, and 7E15-52I.  The vector 
plasmids pET20b (tag-less) and pET30a (designed to contain a 6 histidine residue affinity tag) 
(GE healthcare) were used. Heat shock transformation was utilized to uptake the vectors 
containing the engineered DNA into E. coli cells. DNAs of 7E15 and 7E15-bom were cloned and 
inserted into the vectors.  First, 0.75 µL of DNA was combined with 50 µL of competent cells, 
and the solution was placed in ice for 30 minutes to allow diffusion of DNA through the 20% 
glycerol solution bathing competent cells. Next, the mixture was dropped in a 42 °C water bath 
for precisely 90 seconds to allow DNA uptake by the competent cells. The cells were then 
promptly returned to the ice bucket for 2 minutes, after which they were given 75 µL LB 
medium and incubated for 30 minutes at 37 °C. The cells were then streaked with a sterile 
triangle onto an agar plate containing antibiotic and were allowed to incubate overnight at 37 °C, 
upside down. An additional plate containing cells without DNA was incubated as a negative 
control.  
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Figure 3.1 Plasmid vector map of pET30a. Taken from [30]. 
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3.2.3 Expression of His-7E15 and 7E15 
  A bacterial colony was inoculated and incubated overnight in LB medium and 2.5 mM 
ampicillin or kanamycin, and centrifuged (Sorvall RC SB Plus Centrifuge, ThermoScientific, 
Bruswick, NJ) 4.410 x 10
3
 g for 15 minutes at 5°C. The cell pellet was diluted 1:20 with LB 
medium and appropriate and  transferred to a flask and incubated at 37 °C in a shaker (Shaker 
Controlled Environment Incubator). 
The optical density of each sample at 600 nm was recorded every 30 minutes using UV 
spectrophotometer (Shimadzu Scientific Instruments, Norcross, GA). When the optical density 
(OD) reached 0.6 for BL21 (DE3), Rosetta PLysS, and BL21 (DE3) pLysS, and 0.5 for Tuner 
cells, flasks were induced with Isopropyl β-D-1-thiogalactopyranoside (IPTG). The BL21 (DE3), 
BL21 (DE3) pLysS, and Rosetta pLysS flasks required only 0.25 mM IPTG, while the Tuner 
flasks required 0.5 mM. The shakers were adjusted to the desired temperature either 37 °C or 
30°C, for the duration of cell growth. The flasks were collected and centrifuged at 3.842 x 10
3
 g 
for 20 minutes when the flasks have grown 4 hours or overnight. The cell pellet collected and 
stored at -20 °C until purification. KaleidaGraph software (Synergy Software, Reading, PA) was 
used to plot the optical density versus time plots. Image J software (Version 1.37) was used to 
quantify band thickness as a result of expression on the 15% acrylamide SDS-PAGE gels. 
3.2.4 Optimization of His-tagged 7E15 by Adjustment of Temperature and IPTG 
Concentration at Induction and Purification with Arginine 
As described earlier (section 1.6.1), several factors were found to affect expression level. 
In this section the temperature and IPTG level were adjusted to optimize the parameters for the 
previously low expression level of His-7E15. The expression protocol detailed in sections 2.2.3 
was carried out as stated with a pET30a vector. At the point of induction some flasks received 
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0.2, 0.4, 0.6, 0.8 and 1 mM IPTG. The effectiveness of expression was evaluated by band 
intensity on the SDS-PAGE gel. Expression at 37 °C and 30 °C took place 4 hours after 
induction.    
The protein was purified. Cell pellet was resuspended three times in PBS containing 1% 
Triton x-100, and centrifuged for 30 minutes. The cell pellet was dissolved in 1M arginine and 
left on the shaker overnight at 4°C. The following day, the mixture was centrifuged to separate 
insolubilzed protein and the supernatant was found in the supernatant. Size exclusion 
chromatography was performed and SDS-PAGE samples were collected of the supernatants and 
cell pellets after sonication, washing, and solubilization. 
3.2.5 SDS-PAGE gel  
Prior to induction and hourly post induction, expression samples were collected, 
centrifuged at 9.757x 10
3
 g for 1 minute in an eppendorf centrifuge and the supernatant was 
discarded. To each eppendorf, a 1:10 ratio of sample buffer comprised of 5% ß-SH EtOH was 
added to create a reducing environment and sodium dodecyl sulfate (SDS) was added to denature 
the protein. Addition of SDS causes the protein to become negatively charged and linearized. 
Subsequently, separation on the gel by migration to the positive pole is a representation of size 
and not shape or charge [31]. Samples were boiled 10 minutes to dissociate hydrogen bonds and 
denature the protein, so it would be easily detectable on a 15% acrylamide SDS-PAGE gel 
(Sigma). 
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Figure 3.2 Shows the effect of adding SDS to proteins prior to running through a gel: negative 
charges from SDS disrupt positive charges by side chains of protein and the protein becomes 
negatively charged and linearized, which enables it to migrate to the positive pole during 
electrophoresis. Taken from [31].   
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3.2.6 Purification with Arginine Followed by Denaturing Conditions  
Frozen cell pellet was thawed, suspended in PBS, benzonase nuclease, DTT and serine 
protease inhibitors, and sonicated 6 times, 20 seconds each time in five minute intervals. 
Sonication is a technique that breaks the bacterial cell walls in order to extract expressed protein 
trapped in the cytoplasm of the cell. High energy sound waves are applied to a sample in a water 
bath (for even distribution) which causes breakage of the cell membrane [32]. Cells were further 
broken by French press, which is another method that passes a sample through a high pressure 
chamber. The release of sample back to atmospheric pressure through the valve causes rupture of 
the cell wall, without the heat associated with sonication [32]. The mixture was then centrifuged 
at 1.2947 x 10
4
 g for 30 minutes and supernatant was discarded. The cell pellets were then 
washed three times with 2% Triton X-100, a detergent used to clear debris, with centrifugation at 
1.2947 x 10
4
 g for 20 minutes between each washing. Cell pellet was observed as it turned whiter 
after every wash, and the supernatant was discarded each time. Next, the cell pellets were 
dissolved in 30 ml of 2 M arginine (pH 8.0), a solubilizer, and stirred overnight at a temperature 
of 4 °C, 25 °C, or 37 °C to completely solubilize the cell pellets.  
The following morning, dialysis was performed twice for 2 hours with 10 mM Tris buffer 
(pH 7.4), and once overnight. Subsequently, the solution was centrifuged at 1.2947 x 10
4
 g for 20 
minutes, keeping the supernatant this time, and the pH was adjusted to 7.0. Then, 8 M urea was 
added to the protein and it was placed on an agitator overnight. Dialysis with 4 M urea was 
performed the next morning for 4 hours in order to refold the protein. Dialysis was performed 
with 2 M urea for 4 hours. For overnight dialysis, the buffer was changed to 10 mM Tris. The 
following day, the protein was dialyzed again with 10 mM Tris 2 times for 2 hours, and pH was 
lowered below 3.0 by HCl. Protein was then manually filtered with a 0.45 µM filter, and then 
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injected into a cation exchange column in the FPLC. Pure protein was then concentrated with 
Nitrogen Pressure in an Amicon concentrator (depending on the final concentration). This 
method is similar to studies done by Umetsu [33]. 
3.2.7 Purification Using Denaturing Conditions  
 Post analyzing the results from the purification method described in the previous section, 
a second method was developed, omitting the step with arginine. Frozen cell pellet was thawed, 
suspended in PBS, benzonase nuclease, DTT and serine protease inhibitors, and sonicated 6 
times, 20 seconds each time in five minute intervals. Cells were further broken by French press. 
The mixture was then centrifuged at 1.2947 x 10
4
 g for 30 minutes and supernatant was 
discarded. After the cell pellet is washed with Triton x-100 and centrifuged, it is dissolved in 8 
M urea at room temperature for 2 hours. The protein is then placed in dialysis with 4 M urea for 
2 hours at 4 °C overnight, followed by 2 M urea for 2 hours. Next, the protein is placed in 
dialysis 3 times with 10 mM Tris for 2 hours and is further purified by either the cation exchange 
(having lowered the pH and filtered the solution) or anion exchange (Q column) FPLC. 
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Figure 3.3 Summarizes the purification procedures via non-denaturing and denaturing 
conditions outlined in sections 2.2.5 and 2.2.6. 
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3.2.8 Determining Protein Concentration  
The concentration of purified protein was determined by using a spectrofluorimeter 
(Shimadzu) to measure the UV absorbance in wavelength range of 350-220 nm.  Two quartz 
cells (1 cm) filled with 800 µL nanopure water were measured from 350-220 nm to create a 
baseline from which absorbance differences would be recorded. One of these cells was left while 
the other was emptied and filled with protein. If the absorbance exceeded 2.0, which is outside 
the detection limits, the reading is inaccurate and a 1:16 dilution was usually performed to re-
measure the sample.    
CD2 and its variants have two active tryptophan residues capable of an absorption 
spectrum at 280 nm. When the absorbance spectrum resembles that shown in Figure 3.4, with a 
typical maximum peak at 280 nm and  a “shoulder” (shown by the arrow), it is an indication that 
the protein has a good tertiary structure similar to the parent protein (CD2).  Furthermore, this 
spectrum can indicate the level of DNA present in the sample. DNA has a typical absorbance at 
260 nm. If the absorbance ratio 260/280 nm is greater than 1, the level of DNA is high and will 
interfere with protein function.    
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Figure 3.4 Typical fluorescence absorbance spectra of protein containing tryptophan residues 
with a maximum at 280 nm and a typical “shoulder” (arrow).   
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Protein concentration is obtained by subtracting the absorbance at 350 nm from the 
absorbance at 280 nm and then using Beer’s law with a calculated extinction coefficient. 
A= εcl                                                                                 (Equation 3.1) 
Using online data base Protein Calculator [34] and experimentally, the molar extinction 
coefficient (ε) was calculated based on the content of tryptophans, tyrosines, and disulfide bonds 
in the protein; for wild-type CD2, which lacks disulfide bonds, Protein Calculator estimates 
ε=13940 M-1cm-1.  Experimentally, the value for CD2 and 7E15 (and its tagged version His-
7E15), which has mutations that do not involve aromatic residues, is 11700 M
-1 
cm
-1
.  The 
coefficient for His-7E15-bom was determined by Julian Johnson in his thesis to be 16500 M 
-
1
cm
-1
  [35].  
3.3 Results and Discussion 
3.3.1 Expression of Tag-less 7E15 
 The expression of 7E15 was performed with tag-less vector pET20b at 30 °C overnight in 
LB medium with E. coli cell strain BL21 (DE3) pLysS.  Overnight expression at a low 
temperature was chosen to enable the formation of inclusion bodies without the effect of 
degradation.  The optical density graph is exponential to the point of induction, at about 0.600 at 
600 nm. At induction, the cells received 0.25 mM IPTG and expressed overnight, until the 
harvest point. The SDS-PAGE shows that before induction, basal expression of other proteins 
was low, as is expected of pLysS cell strain. After the addition of IPTG, the engineered protein 
was produced as optical density increased, demonstrating a successful expression outcome 
(Figure 3.5). Figure 3.6 shows evidence that the conditions used for expression were optimal. At 
30 °C overnight induction, the expression bands are thicker than at 37 °C for 4 hours. 
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Figure 3.5 Expression of 7E15. (A) Growth curve indicative of exponential increase in optical 
density of BL21 (DE3) pLysS prior to induction and curve levels off post induction. (B) SDS-
PAGE showing gradual production of protein with the passage of time, the thickest bands found 
after overnight growth.   
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Figure 3.6 Expression of 7E15 with different temperature conditions. (A) Expression curve 
(above) and SDS-PAGE (below) show protein has been expressed at 37 °C for 4 hours. (B) 
Expression curve (above) and SDS-PAGE (below) showing improved expression when the 
temperature is lowered to 30 °C and the protein is expressed overnight.  
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3.3.2 Optimization of His-7E15 Expression  
The expression level of His-7E15 was optimized by increasing the concentration of IPTG 
administered at induction. Although the optical density curve after 4 hours of expression with 
BL21 (DE3) cells at 37 °C is exponential, a low level of expression is seen after induction with 
IPTG concentrations of 0.2 mM, 0.4 mM, 0.6 mM, and 0.8 mM (Figure 3.7).  However, 
expression under the same conditions except with IPTG concentration of 1 mM yielded thick 
bands on the SDS-PAGE after induction indicative of a high expression level (Figure 3.8).  The 
expression product was mostly in inclusion body, especially because the expression level is high 
and because the temperature is high (37°C). This is evidenced on SDS-PAGE  by the presence of 
protein in the cell pellet after the cell lysing step in purification rather than in the supernatant.  
The expression yield is higher than in the pGEX-2T vector. A possible reason for increased yield 
after raising the IPTG level in the pET30a vector may be tied to the affinity of IPTG to the 
repressor protein unique to each vector.  Purification with size exclusion chromatography shows 
protein in fractions 11 and 12, while the peaks corresponding to fractions 7 through 9 are DNA. 
The yield was 44 mg per 1 gram of cell pellet.  
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Figure 3.7 SDS-PAGE and optical density curve of the final point of expression of His-7E15 at 
37 °C (4 hours) with BL21 (DE3) cells. The optical density curve is exponential, yet the gel 
shows a low level of expression after induction with IPTG concentrations 0.2-0.8 mM.  
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Figure 3. 8 SDS-PAGE and optical density curve of the final point of expression of His-7E15 at 
37 °C (4 hours) with BL21 (DE3) cells. The optical density curve shows exponential growth, and 
the gel shows a thick band indicative of a high level of expression after induction with 1 mM 
IPTG.  
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Figure 3.9 Purification of His-7E15 by size exclusion chromatography shows protein in 
fractions 11 and 12 and a DNA peak in fraction 8 (confirmed by DNA gel).  
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3.3.3 Purification of Tag-less 7E15 with Arginine Solubilization Followed by Denaturing 
Conditions  
 Cell pellet was subjected to French press followed by sonication for cell lysis. The 
inclusion bodies formed during expression were found in the cell pellet after centrifugation, and 
were washed with 2% Triton X-100, a detergent to remove lipid-soluble waste. After 
solubilization with 2 M arginine, a large quantity of the protein remains in the cell pellet and is 
not solubilized well. When the supernatant is solubilized in 8 M urea and placed in dialysis with 
4 M urea, followed by 2 M urea, followed by 0 M urea (10 mM Tris buffer), there are less 
impurities on the SDS-PAGE band representing the protein (Figure 3.10). 
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Figure 3.10 Purification of tag-less7E15 with arginine solubilization, followed by denaturing 
conditions. Following cell lysis, protein is in the cell pellet, which is washed with Triton X-100. 
Protein is dissolves poorly in 2 M arginine and following denaturation is refolded and pure (10 
mM Tris samples).  
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 Temperature-dependent arginine solubilization was tested in attempt to optimize protein 
solubilization in 2 M arginine. Cell pellet was solubilized in arginine in different temperatures 
and the effect of temperature on the quantity of solubilized protein was observed. To this end, 
cell pellet was purified and solubilized with arginine at 4°C, room temperature, and 37 °C for 
each temperature.   The concentration of soluble protein was measured following solubilization 
and was found be to highest for room temperature, followed by 4 °C and then 37°C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 77 
 
 
 
 
 
 
 
 
Table 3.2 Arginine solubilization temperature relative to concentration of soluble protein shows 
room temperature is favored for soluble protein.  
 
Arginine 
Solubilization 
Temperature 
Absorbance 
280nm 
Concentration 
(µM) 
37°C 0.6588 47.26 
25°C 0.7198 51.64 
4°C 0.6362 45.64 
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Samples of each temperature were sent to 1D NMR and were run to examine protein 
structure. Tryptophans at positions 7 and 32, along with a tyrosine residue at position 76, are 
visible, typical findings in CD2 that suggest correct structure. At room temperature these peaks 
are seen with greatest resolution (Figure 3.11).  A UV scan was performed to test the protein 
structure after refolding and to test the reliability of the refolding method since it is an 
unconventional way to purify protein (Figure 3.12). The tryptophan fluorescence spectrum below 
shows protein refolds back to its native conformation resembling CD2 (Figure 3.15). The total 
yield from 2.3 L expressed cell culture is shown below (257.8 mg).  Per 1 g cell pellet, 11.68 mg 
protein were obtained, remarkably higher than the yield from GST purification by at least 10 fold 
(Figure 3.12).  
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Figure 3.11 Arginine solubilizaton samples sent to 1D-NMR  
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Figure 3.12 UV spectrum of protein after arginine/ urea refolding method shows reliability of 
method as protein refolds back to its native conformation resembling CD2. The total yield from 
2.3 L expressed cell culture is shown below (257.8 mg). 
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3.3.4 Purification of Tag-less 7E15 Under Denaturing Conditions 
 Cell pellet was purified omitting the solubilization step of arginine. After cell lysis the 
protein was found in the cell pellet as expected. Solubilization in urea was effective, and a small 
quantity of protein was found in the cell pellet after solubilization, in contrast to arginine 
solubilization, which left most of the protein in the cell pellet (Figure 3.13). The protein was 
refolded and soluble after dialysis with Tris. 
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Figure 3.13 Purification of tag-less 7E15 under denaturing conditions. Protein was found in cell 
pellet after cell lysis, and was found in the supernatant post-solubilization with urea. The cell 
pellet after urea shows that solubilization was effective, as little protein remained insoluble.  
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Additional purification in SP and Q columns shows higher yields than obtained per liter 
of GST purification (Figure 3.14).  The SP column gave 17.3 mg protein per 10 mL injection, 
which is theoretically 156 mg per liter of expressed cell culture. The Q column gave 25.9 mg per 
10 mL injection, which is theoretically 234 mg per liter of expressed cell culture.   
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Figure 3.14 Chromatograms from FPLC purification of 7E15 show high yield. (A) Peak 
obtained in fractions 17-20 from a 10 mL injection into the SP column yields 17.3 mg protein. 
(B) Peak from a 10 mL injection into the Q column yields 25.9 mg protein in fractions 15 and 
16.  The arrows from the gel band correspond to the peaks on the chromatogram. 
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 A CD spectrum and tryptophan fluorescence spectrum are the strongest evidence that the 
protein regains its secondary and tertiary native structure after denaturation with urea and that the 
refolding method is reliable. The CD structure of refolded 7E15 shows a typical β sheet 
conformation with a minimum point at 219 nm. This secondary structure is similar to what is 
typically seen in the CD structure of CD2 [36]. Additionally, compared to protein after GST 
purification, which has been shown to refold correctly by previous experimentation, the 
tryptophan fluorescence spectrums of both refolding purification methods are similar, indicating 
tertiary structure resemblance. A total of 266 mg of protein were obtained from purification. For 
every gram of cell pellet 11.77 mg protein were extracted via refolding, which is higher than 
arginine/urea purification and significantly higher than GST purification (Figure 3.15).   
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Figure 3.15 Structural studies of 7E15 post refolding purification. (A) CD spectrum of 7E15 
shows a similar secondary structure conformation as seen in CD2 [36]. (B) Tryptophan 
fluorescence spectrums of 7E15 purified by different methods. The arginine/urea method (shown 
in green) and the urea method (shown in red) show tertiary structure resemblance to GST 
purification (shown in blue).  
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3.4 Conclusions and Future Work  
 A rapid, effective method for generating high yield of 7E15 has been established by 
generating and purifying inclusion bodies. The theoretical yield for a liter of expressed cell 
culture has risen impressively to 156 mg -234 mg pure protein from 1 L expressed cell pellet. 
The first step, over-expression of 7E15 as inclusion bodies, has been performed successfully 
under conditions established in chapter 2.  Expression of His-tagged 7E15 has been optimized by 
adjusting the IPTG level to 1 mM.  
 Purification of obtained inclusion bodies via two methods was tested. The first method 
was solubilization in arginine followed by denaturation in urea. The objective was to test 
whether solubilizing the protein first would boost the level of soluble product after denaturation. 
The protein did not solubilize well in arginine, as indicated by SDS-PAGE, and only a small 
quantity of protein was extracted. Solubilization of protein in arginine seemed to depend on 
temperature, with more soluble amounts of protein at room temperature than at either extreme 
(37 °C or 4 °C). The temperature of solubilization in arginine was raised to room temperature to 
increase the level of solubilized protein. Purification by direct immersion of cell pellet in 8 M 
urea at room temperature showed a high level of solubilized protein. Protein which was not 
solubilized was centrifuged and separated.  
 The yields from arginine/ urea and urea were 11.68 mg/ 1 g cell pellet and 11.77 mg/ 1 g 
cell pellet, respectively, both of which are an improvement from traditional GST purification. 
Additionally, structural studies with CD and tryptophan fluorescence indicate that refolding 
methods can reliably generate protein that does not lose its native conformation.  
 Although purification yield from urea is not significantly greater than the yield from 
arginine/urea, it is still advisable to use the urea method for several reasons.  First, optimization 
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of a rapid and efficient purification method includes removing extra steps which may cause loss 
of protein. Furthermore, the contribution of solubilized protein from the arginine step to the total 
yield is not significant enough to warrant an extra purification step. In fact, loss of protein in the 
cell pellet and low solubilization are reasons to omit this step.        
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CHAPTER 4: PROTEIN-BASED CONTRAST AGENTS 
4.1 Site-Directed Mutagenesis to Create 7E15 Charged Variants  
Charged variants of ProCA1 (or 7E15) were created by Dr. Anna Wilkins Maniccia 
utilizing the design approach with site-directed mutagenesis [17]. One of the intentions of 
creating 7E15 charged variants was to study whether varying the charge or coordination residue 
type in the metal binding pocket would affect calcium binding compared to the template, 7E15, 
within a fixed binding site [15]. Drs. Anna Maniccia and Wei Yang have shown that calcium 
binding affinity is increased as the charge in the binding pocket is increased.  CD2.7E15 has a 
strong metal binding affinity for Tb
3+
 (Kd~10
-10
 M), as shown by FRET, and a weak calcium 
binding affinity (Kd of 0.15 mM). In later work, CD2.7E15 was shown to be an excellent MRI 
contrast agent with a strong Gd
3+
 binding affinity (Kd~10
-10
 M), as demonstrated with a metal 
buffer system, and significantly improved relaxivity [1]. 
It is not clear whether other charged variants are good candidates for MRI contrast 
agents. Among several available charged variants created, three -5 and -4 charged variants have a 
strong potential as MRI contrast agents. Residue 64 in 7E15 was changed to glutamate (called 
EEDDE in [15;17] or 7E15E throughout this paper) to create a -5 pair, 7E15/7E15E that differs 
by a methylene group. This residue was changed to glutamine or aspargine (called EEDDQ and 
EEDDN in [15;17] or 7E15Q and 7E15N throughout this paper), a -4 pair that also differs by a 
methylene group. The objective of this chapter is to examine Tb
3+
, Gd
3+
, and Zn
2+
 binding with 
different charged variants and to examine the suitability of these proteins as the next contrast 
agents.   
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Table 4.1 Summary of the residues in 7E15 charged variants; red refers to positive, blue refers to 
negative, and black refers to neutral amino acids [15].  
 
         Residues       
Protein 15 56 58 62 64 Charge 
CD2WT N E L D K 0 
7E15 E E D D D -5 
7E15E E E D D E -5 
7E15Q E E D D Q -4 
7E15N E E D D N -4 
EENDN E E N D N -3 
NENDN N E N D N -2 
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4.2  Methods and Materials 
4.2.1 Cloning and Transformation 
 The genes for 7E15 and its charged variants were cloned with PCR by Dr. Anna Wilkins 
Maniccia in accordance with the protocol in her dissertation [37]. The transformation procedure 
took place as described in section 2.2.2. The exceptions are that BL21 (DE3) E.coli competent 
cells and vector pET-20b, designed to contain no affinity tag for purification, were used instead.  
4.2.2 Over-expression  
A bacterial colony was inoculated and incubated overnight in LB medium with 2.5 mM 
ampicillin. Flasks containing 1 L LB medium and 2.5 mM ampicillin received 50 mL of the 
culture grown overnight, and the 1 L flasks were incubated at 37 °C in a shaker (Shaker 
Controlled Environment Incubator). 
The optical density (OD) of each sample at 600 nm was recorded every 30 minutes using 
UV spectrophotometer (Shimadzu Scientific Instruments, Norcross, GA). When the OD reached 
0.6 for BL21 (DE3), Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to cultures. The 
BL21 (DE3) strain required 0.25 mM IPTG. The shakers were adjusted to 37 °C for the duration 
of expression. The cell pellets were collected by centrifugation at 4.410 x 10
3
 g for 20 minutes 
after the cultures have grown overnight, or when the cell population began to level off. The cell 
pellets were stored at -20 °C until purification. KaleidaGraph software (Synergy Software, 
Reading, PA) was used to plot the optical density versus time plots. Image J software (Version 
1.37) was used to quantify band thickness as a result of expression on the 15% acrylamide SDS-
PAGE gels. 
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4.2.3 Purification Via Urea Refolding Method  
 Purification was performed using the refolding method as described in section 2.2.7 with 
modification. Cell pellet from expression (approximately 5 g) was suspended in lysis buffer 
containing PBS. Benzonase nuclease (60 µL) and serine inhibitor PMSF (200 µL) were added. 
The cell pellet was broken using sonication (6 times for 20 seconds each), French press (1500 
psi), or cell disruption. The mixture was then centrifuged (S34 rotor) at 1.2947 x 10
4
 g for 30 
minutes and supernatant was discarded. The cell pellets were then suspended in 20 mL of 2% 
Triton X-100, and centrifuged at 1.2947 x 10
4
 g for 20 minutes between each of three washings. 
Next, the cell pellet was dissolved in 25 mL of 8 M urea (pH 7.3) and stirred overnight at 4 °C to 
completely solubilize the cell pellet.  
The solublized cell pellet was centrifuged for 20 minutes at 1.2947 x 10
4
 g. PBS was then 
added drop-wise for a final concentration of 4 M urea and the solution was stirred for 2 hours. 
Next, the solution was placed in dialysis for 4 hours with 2 M urea, followed by addition of 
proteases (200 µL) and overnight dialysis with 2 L 10 mM Tris-HCl buffer (pH 7.4). The 
dialysis bag has pores which allow molecules with molecular weight over 3.5 k Da to remain in 
the bag. The dialysis buffer was changed to 10 mM Tris the following morning, which was 
replaced to gradually remove urea from the solution. Subsequently, the solution was centrifuged 
at 1.2947 x 10
4
 g for 20 minutes, and the supernatant was kept.  
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Figure 4.1 Summary of the urea refolding method 
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4.2.4 Anion Exchange Chromatography Purification Based on Salt Gradient  
 The Q-column was used in an ÄKTA prime FPLC instrument (Amersham Biosciences, 
Piscataway, NJ). The supernatant was filtered using a 0.45 µM manual filter. Protein was 
injected into the column, and the flow rate was 1-2 ml/min. The binding buffer, buffer A (pH 
8.5) contained no salt while the elution buffer, buffer B (also pH 8.5), contained 1M NaCl. The 
column was washed with buffer A over three column volumes (CV), followed by a gradually 
increasing percentage of buffer B to 70% over 9 CV. Lastly, the column was washed with buffer 
B over 1-2 CV. The protein eluted in 1.5 mL fractions.  
4.2.5 Cation Exchange Chromatography Purification Based on pH Gradient 
 The conditions for the SP column were as follows. The pH of the protein was lowered to 
3.0 by adding HCl, and the protein was filtered manually with a 0.45 µM filter. The protein was 
injected and the flow rate was 1-2 ml/min. Buffer A has a pH of 4.0 while Buffer B has a pH of 
8.0.  
4.2.6 Far Ultraviolet Circular Dichroism 
The purpose of this experiment was to observe the effect of adding calcium on the 
conformation of 7E15 variants with a circular dichroism (CD) instrument (JASCO, J-810 
spectropolarimeter). Protein samples were diluted with 20 mM Tris (pH 7.4) buffer to a final 
concentration of 50 µM. The first sample contained 50 uM protein and 2 mM EGTA in 200 uL 
buffer. The second sample contained 50 µM protein and 2 mM Ca
2+
 in 200 uL buffer. The 
samples were placed in a 2 cm UV cell and scanned from 190-260 nm. Ten scans were averaged 
at 50 nm per minute. The spectra were corrected by subtraction from buffer samples.   
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4.2.7 Determination of Kd of Charged Variants to Tb
3+
 Using Fluorescence Resonance 
Energy Transfer (FRET) Assay 
The binding affinity of CD2.7E15 and its variants to terbium was determined using 
spectra obtained from FRET assay with a SC-500 PTI spectrofluorimeter.  Two sets of titrations 
each were performed in triplicate with 7E15 and 7E15N. The first set was performed in 10 mM 
chelex Tris-HCl, pH 7.4, while the second set was performed in 20 mM PIPES, 10 mM KCl, pH 
6.8. In both cases, the final protein concentration was 5 µM, and the cuvette had 1 cm path 
length quartz cell. Incubation time upon addition of more terbium was 5 minutes. The excitation 
was set to 282 nm, a tryptophan excitation wavelength, while the emission was set to 500-600 
nm. The integration time was 0.2 seconds. To reduce Raleigh scattering, a glass plate was used 
as a filter. The excitation and emission slit widths were 1.0 and 1.8 mm, respectively.  
The Kd of 7E15 to terbium was calculated after correcting the baseline with Kaleidagraph 
by subtracting free terbium from bound terbium. The data was fitted according to the Equation 
4.20, as published, which was derived from the following equations where P: Protein; M: Metal 
Ion; MP: Complex of protein and metal ion; F: Fraction of complex in total protein [38]: 
 
(Equation 4.1) 
 
(Equation 4.2) 
 
(Equation 4.3) 
 [MP] is the only species that fluoresces and gives off intensity.  F defines the formation of [MP] 
based on how much metal is added. The fraction increases based on how much complex is 
formed. 
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Using Equation 4.4: 
 
Kd can be estimated by curve fitting of F~[M]T with a constant protein concentration. 
The equation we use in Kaleidagraph is: 
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Where M1=Kd; M2=[P]T; M0= [M]T 
F is proportional to intensity of fluorescence.  
 
In the fitting curve, fluorescence intensity is accounted for by multiplying each side by 10
5
. The 
equation becomes: 
 
Where M1= [P]T; M2= Kd; M3= Maximum Intensity, i.e 6 x 10
5  
[38]. 
4.2.8   Determination of Affinity of 7E15 Charged Variants to Gd
3+
 and Zn
2+
 by 
Competition with Molecular Probes Dyes  
The Gd
3+
 binding affinity of charged variants was tested using a competition assay with  
fluorescent dye Fluo-5N, which has a published Gd
3+
 Kd of 3.8 + 0.2 x 10
-12
 (Molecular Probes, 
Invitrogen). Experiments were modeled after previously published data [39]. The titrations were 
performed in duplicate using a SC-500 PTI spectrofluorimeter. The emission scans were from 
500-650 nm and a 1 cm path length cell was used. The excitation wavelength was 488 nm, and 
the excitation slit widths ranged from 0.31-0.36 mm while emission slit widths ranged from 
0.41-0.46 mm. The integration was 0.2 seconds, the step size was 1, and the incubation time was 
5 minutes between each scan. The glass slide was left out of the fluorimeter. The buffer 
conditions were 10 mM Tris-HCl, pH 7.4 or 20 mM PIPES, 10 mM KCl, pH 6.8. The Fluo-5N 
and Gd
3+
 concentrations were 10 µM or 5 µM, diluted with buffer.     
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 Fluo-5N and Gd
3+
 were mixed together in a 1:1 ratio for all experiments. Gd
3+
 was 
competed out with by gradual addition of 7E15 charged variants in 20 µM intervals until 
saturation, a final concentration of 150 µM. The effect of dilution was accounted for and 
calculated using excel. The emission scan showed a maximum fluorescence intensity at 519 nm, 
which was fitted and plotted versus protein concentration using Kaleidagraph to obtain the 
apparent dissociation constant, Kapp, an approximation of Kd that does not include the binding 
affinity of Fluo-5N and Gd
3+
. The 1:1 fitting equation used is a modified version of Equation 
4.22, where M1= [P]T; M2= Kd; M3= Maximum Intensity, i.e 6 x 10
5
:  
 
The Kd value was obtained using the following published equation, where Kd2 is the protein 
affinity, Kd1 is the Gd
3+
- Fluo-5N affinity [39]:       
 
As a control experiment, a titration with EDTA was performed. As well, a titration was 
performed where the intensity of Fluo-5N (minimum intensity) and the intensity of Gd
3+
-Fluo-
5N (maximum intensity) were graphed to characterize the intensity range of the experiment.  
 The zinc affinity of charged variants was tested using a competition assay with 
fluorescent dye FluoZin-1, which has a published Zn
2+
 Kd of 8.2 µM (Molecular Probes, 
Invitrogen). The buffer conditions were 10 mM Tris-HCl pH 7.4, the excitation slit widths 
ranged from 0.25-0.30 mm, while emission slit widths were 0.50. The emission was recorded 
from 500-650 nm while the excitation wavelength was 495 nm. The protein was added in 8 µM 
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intervals until saturation, a final concentration of 125 µM (approximately). The effect of dilution 
was accounted for and calculated using excel.  
4.2.9 Relaxivity Measurements 
 T1 and T2 measurements were performed with a Bruker Minispec and an mq60 NMR 
analyzer, at 25 °C, at a field strength of 1.4 T or 60 MHz. The protein concentration was varied 
against a fixed gadolinium (50 µM). The buffer was 10 mM HEPES, pH 7. Protein concentration 
versus 1/T1 or 1/T2 was plotted in KaleidaGraph and samples with protein to gadolinium ratio of 
1:1, 1.5:1, 2:1, and 3:1, the saturation point of the relaxivity plot, were used to determine the 
average relaxivity. T1 and T2 were fitted using Equations 4.25 [46] and 4.26 [46], respectively, 
where M0  represents the initial magnetization. Relaxivity was calculated using Equation 1.6.  
    
4.3 Results and Discussion  
4.3.1 Expression of CD2.7E15 Charged Variants 
CD2.7E15 charged variants, 7E15, 7E15N, 7E15E, 7E15Q were expressed in LB 
medium using BL21 (DE3) E. coli cell strain and tag-less vector pET20b at 37 °C overnight. The 
conditions were selected with the intention of producing inclusion bodies for purification. When 
the optical densities reached 0.600 at 600 nm, the flasks were induced with 250 µM IPTG 
(Figures 4.2 A).  Following overnight expression, they were harvested. The SDS-PAGE gels 
show thickening bands with the passage of time, which illustrates that protein was formed during 
expression and specifically after induction with IPTG (Figures 4.2 B). 
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Figure 4.2 Expression of 7E15 (top), 7E15N (middle), and 7E15E and 7E15Q (bottom). (A) 
Optical density curve showing steady increase of cells at 37 °C with tag-less vector pET20b and 
induction point. (B) SDS-PAGE gel showing gradual thickening of 7E15-variant bands after 
induction.  
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4.3.2 Purification, Mass Spectra, and Circular Dichroism of Analysis CD2.7E15 Charged 
Variants 
CD2.7E15 charged variants were purified using the refolding method followed by cation 
exchange chromatography. SDS-PAGE gel shows that following French press, proteins were in 
cell pellet, due to inclusion body formation during expression. Following wash with 2% Triton 
X-100, proteins remained in the cell pellet and a negligible quantity was lost in the supernatant 
(discarded).  Addition of 8 M urea dissolved the pellets, and proteins were found in the 
supernatant. Gradual removal of urea resulted in refolding proteins in the soluble form, and 
following dialysis in 10 mM Tris-HCl (pH 7.4) and centrifugation, most protein was found in 
supernatant, and any misfolded protein was found in the cell pellet (discarded). Protein was 
injected into the cation exchange column (FPLC system) after adjusting the pH to 3.0 with HCl. 
The peak in fractions 29-31 was found to contain protein with high purity (confirmed by SDS-
PAGE) (Figure 4.3). The final average concentrations and yields (in mg) for 7E15 charged 
variants are shown in Table 4.2.  The proteins were analyzed with an ABI 4800 MALDI 
TOF/TOF mass spectrometer by Yanyi Chen to verify refolding after purification. The 
experimental masses shown on the MS spectra are within less than 2% error than the calculated 
weights (Figure 4.4).   
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Figure 4.3 Purification of 7E15 charged variants with SDS- PAGE gel of refolding method (top 
left) followed by SDS- PAGE gel and chromatogram of ion exchange chromatography (bottom 
right).  
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Table 4.2 Shows absorbance ratio 280/260 nm, molar absorptivity, molar mass, final 
concentration, and average final yield in milligrams per liter of expressed 7E15 charged variants.  
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Figure 4.4 Mass spectra of 7E15 charged variants obtained with ABI 4800 MADLI TOF/TOF 
mass spectrometer instrument. 
%
 I
n
te
n
si
ty
  
%
 I
n
te
n
si
ty
  
%
 I
n
te
n
si
ty
  
%
 I
n
te
n
si
ty
  
 105 
 
Studies of secondary and tertiary conformation of charged variants upon binding to 
metals such as calcium and lanthanides were studied extensively by Dr. Anna Wilkins 
Maniccia with CD, FRET, and NMR, and details have been published [40].  The simplified 
study below, modeled by Dr. Maniccia’s work, was performed to verify the secondary 
structure of purified charged variants and to study the effect of adding calcium and 
gadolinium. The CD spectra below show a negative peak at 219 nm, implying a β-sheet 
secondary conformation typically exhibited by CD2. Upon adding calcium, there is no 
significant change in conformation, as shown in previous studies [40]. When gadolinium is 
added a slight change in conformation observed, due to precipitation (Figure 4.5 A, B, C, D). 
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Figure 4.5 Secondary structure studies by CD. (A) 7E15 with EGTA, Ca
2+
, and Gd
3+
. (B) 7E15 
with EGTA, Ca
2+
, and Gd
3+
. (C) 7E15N with EGTA, Ca
2+
, and Gd
3+
. (D) 7E15N and 7E15E 
each with EGTA, Ca
2+
, and Gd
3+
. 
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4.3.3 Determination of Kd of 7E15 Charged Variants to Tb
3+
 by FRET Titration 
Metal binding studies were performed to determine the binding affinity of the charged 
variants to terbium. Terbium and calcium have similar atomic radii (~180 pm) and behave 
similarly, except calcium is spectroscopically inactive and binding cannot be studied with this 
method. FRET method utilizes the fact that tryptophan can transfer the energy from excitation to 
terbium, because the excitation of tryptophan alone does not produce a recordable signal.  At 282 
nm, tryptophan is excited and emits the energy at a wavelength of 340 nm, which is the 
wavelength range that terbium absorbs energy. Between 500 and 600 nm, terbium emits the 
energy absorbed from tryptophan at 545 nm and 595 nm (two of four possible wavelengths).  
 
 
 
 
 
 
 
 
 
 
 108 
 
 
 
 
 
Figure 4. 6 Cartoon illustrating donor emission (tryptophan) and acceptor absorption (terbium) 
spectral overlap. Taken from [41]. 
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The fluorescence of the 7E15-terbium complex increases with increasing terbium 
concentration until saturation (~20 µM), when no more protein is available to bind terbium. The 
maximum at 545 nm is fitted. The curves were fitted using the equation described in the methods 
portion (Equation 4.20) and 1:1 binding is clearly seen (Figures 4.7. and 4.8.). Table 4.3 
summarizes the approximate Kd values in µM, 4.45+ 0.65 for 7E15, and 8.97 + 0.87 for 7E15N; 
previous results show a binding affinity of CD2.7E15 to terbium of 0.4 + 0.2 µM [40].  
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Figure 4.7 Fluorescence intensity of Tb
3+
 as a function of wavelength. Titration with 5 µM 
CD2.7E15 in 10 mM chelex Tris, pH 7.4, excitation at 282 nm, emission 500-600 nm, maximum 
at 545 nm (fitted to give an approximate Kd in µM).  
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Figure 4.8 Fluorescence intensity of Tb
3+
 as a function of wavelength. Titration with 5 µM 
CD2.7E15N in 20 mM PIPES, 10 mM KCl, pH 6.8, excitation at 282 nm, emission 500-600 nm, 
maximum at 545 nm (fitted to give an approximate Kd in µM). 
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Table 4.3 Summary of the approximate Kd values for 7E15 in 10 mM Tris-HCl, pH 7.4 and 
7E15N in 20 mM PIPES, 10 mM KCl, pH 6.8. Final protein concentration was 5 µM, excitation 
wavelength was 282 nm, and emission wavelength was 500-600 nm.  
 
 
 
 
 
 
 
 
 
 113 
 
4.3.4 Determination of Affinity of 7E15 Charged Variants to Gd
3+
 by Competition with 
 Molecular Probes Dye Fluo-5N 
 
 The binding affinity of 7E15 charged variants to gadolinium was measured using 
fluorescent dye Fluo-5N pentapotassium salt, which has a published Kd to gadolinium of 3.8 + 
0.2 x 10
-12
 and a high sensitivity. The dye itself has fluorescence intensity due to aromatic 
components within its structure (Figure 4.9). A saturation test was performed during which the 
dye was saturated with gadolinium. The maximum intensity peak corresponded to Fluo-5N-Gd
3+
 
while minimum intensity peak corresponded to Fluo-5N (Figure 4.10).  As well, a titration of 
Fluo-5N-Gd
3+
 with EDTA was performed as a control, as EDTA has a Kd to gadolinium of 
approximately 10
-18
 [39] (Figure 4.11).  
Following this, titration of protein gradually into 1:1 ratio of Fluo-5N-Gd
3+ 
showed a 
decrease in fluorescence intensity as saturation is approached. This is because the gadolinium is 
competed out by the protein and 7E15-Gd
3+
 does not have a fluorescence signal. The first trial in 
duplicate with 7E15 took place with 10 µM Fluo-5N and 10 µM Gd
3+
  in  conditions of 10 mM 
Tris-HCl pH 7.4 (Figure 4.12).  An average plot of all trials shows that the Kapp is 1.74; 
calculated Kd value is 6.62 x 10
-13 
(Figure 4.13). The other charged variants were tried using 
these conditions, but the plots were not fitted well because of incomplete saturation due to 
precipitation (but no hydroxide formation).  
The next set of experiments was performed with a lower concentration of dye and metal, 
5 µM Fluo-5N and 5 µM Gd
3+
,  in 20 mM PIPES, 10 mM KCl, pH 6.8. Fluorescence intensity 
versus wavelength was graphed.  The fitted curve at 519max nm displaying Kapp (fitted with 
Equation 4.24) is shown on the top right of each graph  (Figure 4.14, 4.15, 4.16, 4.17). The 
average fitted plot for each charged variant with Kapp is shown (Figure 4.18).   The Kd to 
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gadolinium for each charged variant was calculated using Equation 4.23 and the results indicate 
that CD2.7E15 has the lowest affinity to gadolinium while CD2.7E15Q has the highest affinity 
to gadolinium (Table 4.4).  
 
 
 
 
 
 
 
Figure 4.9 Chemical structure of Fluo-5N, pentapotassium salt Molecular Probes Invitrogen dye. 
Taken from [42]. 
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Figure 4.10 Saturation test. Maximum fluorescence intensity peak corresponds to Fluo-5N- Gd
3+
 
complex, while minimum fluorescence intensity peak corresponds to Fluo-5N. 
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Figure 4.11 Titration of Fluo-5N-gadolinium with EDTA. 
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Figure 4.12 Competition assay with 10 µM Fluo-5N and 10 µM gadolinium in 10 mM Tris-HCl, 
pH 7.4 with CD2.7E15 (added in 20 µM increments until saturation) to determine Kd; excitation 
at 488nm, emission range 500-650 nm (two trials).  
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Figure 4.13 Average plot of 7E15-Gd
3+
  following assay of 10 µM Fluo-5N to 10 µM 
gadolinium in 10 mM Tris-HCl, pH 7.4  indicated Kapp of 1.74 and a calculated Kd of 6.62 x 10
-
13
. 
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Figure 4.14 Competition assay with 5 µM Fluo-5N and 5 µM gadolinium in 20 mM PIPES, 10 
mM KCl, pH 6.8 with CD2.7E15 (added in 20 µM increments until saturation) to determine Kd; 
excitation at 488nm, emission range 500-650 nm (two trials).  
 120 
 
.
 
 
Figure 4.15 Competition assay with 5 µM Fluo-5N and 5 µM gadolinium in 20 mM PIPES, 10 
mM KCl, pH 6.8 with CD2.7E15N (added in 20 µM increments until saturation) to determine 
Kd; excitation at 488nm, emission range 500-650 nm (two trials).
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Figure 4.16 Competition assay with 5 µM Fluo-5N and 5 µM gadolinium in 20 mM PIPES, 10 
mM KCl, pH 6.8 with CD2.7E15Q (added in 20 µM increments until saturation) to determine 
Kd; excitation at 488nm, emission range 500-650 nm (two trials).
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Figure 4.17 Competition assay with 5 µM Fluo-5N and 5 µM gadolinium in 20 mM PIPES, 10 
mM KCl, pH 6.8 with CD2.7E15E (added in 20 µM increments until saturation) to determine 
Kd; excitation at 488nm, emission range 500-650 nm (two trials).
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Figure 4.18 Average plots of competition assay with 5 µM Fluo-5N and 5 µM gadolinium in 20 
mM PIPES, 10 mM KCl, pH 6.8 with CD2.7E15 and charged variants to determine Kd. (A) 
CD2.7E15. (B) CD2.7E15N. (C) CD2.7E15Q. (D) CD2.7E15E. 
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Figure 4.19 Overlaid average plot of competition assay with 5 µM Fluo-5N and 5 µM 
gadolinium in 20 mM PIPES, 10 mM KCl, pH 6.8 with CD2.7E15 and charged variants to 
determine Kd. 
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4.3.5 Determination of Affinity of 7E15 Charged Variants to Zn
2+ 
by Competition with 
Molecular Probes Dye FluoZin-1 
The Zn
2+
 binding affinity to CD2.7E15 was determined by competition assay with 10 µM 
Fluoin-1 and 10 µM Zn
2+
, in 10 mM Tris, pH 7.4. Fluorescence intensity versus wavelength was 
graphed and the point at maximum wavelength 545 nm was used to fit the curve and obtain the 
Kapp (fitted with Equation 4.24), which is shown on the top right of each graph (Figure 4.20, 
4.21, 4.22, 4.23). The average fitted plot of each charged variant with Kapp is shown (Figure 
4.24).  The fitting is not optimal because the concentration of the dye and zinc are high and 
incomplete saturation occurs even with high concentrations of protein. The binding affinity of 
the CD2.7E15 charged variants to zinc was calculated using Equation 4.23. Results indicate that 
CD2.7E15N has the lowest affinity to zinc while CD2.7E15Q has the highest affinity to zinc 
(Table 4.4).  
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Figure 4. 20 Competition assay with 10 µM FluoZin-1 and 10 µM zinc in 10 mM Tris, pH 7.4 
with CD2.7E15 (added in 8 µM increments until saturation) to determine Kd; excitation at 495 
nm, emission range 500-650 nm (two trials). 
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Figure 4. 21 Competition assay with 10 µM FluoZin-1 and 10 µM zinc in 10 mM Tris, pH 7.4 
with CD2.7E15E (added in 8 µM increments until saturation) to determine Kd; excitation at 495 
nm, emission range 500-650 nm (two trials). 
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Figure 4. 22 Competition assay with 10 µM FluoZin-1 and 10 µM zinc in 10 mM Tris, pH 7.4 
with CD2.7E15N (added in 8 µM increments until saturation) to determine Kd; excitation at 495 
nm, emission range 500-650 nm (two trials). 
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Figure 4. 23 Competition assay with 10 µM FluoZin-1 and 10 µM zinc in 10 mM Tris, pH 7.4 
with CD2.7E15Q (added in 8 µM increments until saturation) to determine Kd; excitation at 495 
nm, emission range 500-650 nm (two trials). 
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Figure 4.24 Overlaid average plot of competition assay with 10 µM FluoZin-1 and 10 µM zinc 
in 10 mM Tris-HCl, pH 7.4 with CD2.7E15 and charged variants to determine Kd. 
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4.3.6 Relaxivity of CD2.7E15 Charged Variants 
 The relaxivity of CD2.7E15 and charged variants was measured by changing the protein 
concentration against a fixed concentration of gadolinium. This method highlights the 1:1 
binding mode in CD2.7E15 and the charged variants. Figure 4.25 A-D shows the change in 
relaxation time with increasing protein to gadolinium ratio. Relaxation time decreases as the ratio 
of protein to gadolinium increases, until the point of protein saturation with gadolinium. In 
Figure 4.25 B, the T1 signal of 75 µM 7E15N is significantly lower than the others due to 
instrumental error.  
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Figure 4. 25 Graphs of T1 and T2 for CD2.7E15 and the charged variants show change in 
relaxation time with increasing protein to gadolinium ratio in 10 mM HEPES, pH 7, 25 °C, 1.4 
T. (A) T1 (right) and T2 (left) graphs of CD2.7E15. (B) T1 (right) and T2 (left) graphs of 
CD2.7E15N. (C) T1 (right) and T2 (left) graphs of CD2.7E15Q. (D) T1 (right) and T2 (left) 
graphs of CD2.7E15E. 
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Protein concentrations were then plotted against reciprocal T values (relaxivity), which 
were calculated using Equation 1.6 (Figure 4.26), and fitted linearly. The point where the lines 
cross indicates the concentration at which saturation was observed. Since CD2.7E15 and the 
charged variants exhibit 1:1 binding, the graph began to saturate when the protein concentration 
reached 0.05 mM (in Figures 4.26 B and D) and continued to saturate as the protein to 
gadolinium ratio increased.   
In Figure 4.26 A, the saturation point is reached when the protein to gadolinium ratio is 
1.5:1. Past this point, the relaxivity values decrease sharply. This could be due to several reasons. 
First, although the protein was placed in dialysis with chelex Tris-HCl prior to this experiment, it 
is possible that small quantities of calcium are still present and are bound to the metal site 
(calcium and lanthanides have similar ionic radii). This may have prevented the gadolinium from 
saturating all the protein molecules and the concentration of protein at the saturation point is 
erroneously high. Additionally, during purification, it is possible that a portion of the protein 
misfolded during refolding. This implies that two species of protein with different folding 
properties and binding capabilities to gadolinium are present in the sample.  A CD or tryptophan 
spectrum would be needed to confirm this. 
In Figure 4.26 C, the curve begins to saturate when the protein concentration is 0.05 mM 
and then continues to increase. This could be due to incomplete saturation. Additionally, non-
specific binding of gadolinium to other residues in CD2 is possible. Because of their 
configuration in space, residues D25, D27, D71, and E99 create another potential binding site for 
non-specific binding of calcium or other metals.  Another possibility is experimental error.   
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Figure 4. 26 Relaxivity of CD2.7E15 and charged variants with a gadolinium concentration of 
0.05 mM, in 10 mM HEPES, pH 7, 25 °C, at 1.4 T. Plot of reciprocal T values against protein 
concentration is fitted linearly to determine saturation point. The red, dashed line represents the 
point where the protein to gadolinium ratio is 1:1   (A) CD2.7E15. (B) CD2.7E15Q. (C) 
CD2.7E15E. (D) CD2.7E15N.
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Typically, the point where the protein to gadolinium ratio is 1:1 and above is averaged to 
find the relaxivity. However, because results need to be repeated and optimized, the relaxivity 
value at saturation point was used to determine r1 and r2 for each protein. The r1 and r2 values of 
CD2.7E15 were 22.9 mM
-1
s
-1
 and 33.1 mM
-1
s
-1
, respectively. The r1 and r2 values of CD2.7E15E 
were 22.7 mM
-1
s
-1
 and 33.9 mM
-1
s
-1
, respectively. The r1 and r2 values of CD2.7E15N were 21.9 
mM
-1
s
-1
 and 30.4 mM
-1
s
-1
, respectively. The r1 and r2 values of CD2.7E15Q were 39.5 mM
-1
s
-1
 
and 55.4 mM
-1
s
-1
, respectively. The relaxivity values for CD2.7E15 and the charged variants are 
within the same. Overall, the r1 and r2 values were significantly greater than the relaxivity of Gd-
DTPA (Figure 4.27).   
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Figure 4. 27 Summary of r1 and r2 of CD2.7E15 charged variants in 10 mM HEPES, pH 7, 25 
°C, 1.4 T shows comparable relaxivities to each other, which are significantly higher than the 
relaxivity of Gd-DTPA. 
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4.4 Summary and Significance  
 
The Gd
3+
 binding affinities of charged variants were overall larger than the Zn
2+
 and Ca
2+
  
binding affinities. (Figures 4.19 and Figure 4.24, and Table 4.4). This suggests that CD2.7E15 
and its charged variants will bind to metals such as Gd
3+
 with significantly higher affinity than to 
physiological metals. Strong binding affinities of these contrast agents to Gd
3+
 is important to 
reduce toxic effects of free Gd
3+
.  It is important to note that the zinc binding affinity is not fitted 
optimally. However, the data is comparable to previously published data [1], in which the 
binding affinity of CD2.7E15 (in log Ka) is 6.72, compared to the data in Table 4.4. The metal 
selectivity of Gd
3+
 over Zn
2+
 or Ca
2+
 is significantly higher (Table 4.4). Additionally, the 
relaxivity values for CD2.7E15 charged variants are similar to each other, and overall they are 
significantly higher than the relaxivity of Gd-DTPA. The relaxivity results are preliminary and in 
the future should be repeated. Among the charged variants the difference in binding affinity is 
small and would be more pronounced if more charged variants such as -3 and -2 were tested. 
Still, -4 and   -5 charged variants are suitable candidates for the next contrast agents.  
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Table 4.4 Summary of the Kd values of 7E15 charged variants to Gd
3+
 (5 µM Fluo-5N- 5 µM 
Gd
3+
, in 20 mM PIPES, 10 mM KCl, pH 6.8), Tb
3+
 (5 µM 7E15 or 7E15N, in 10 mM Tris-HCl, 
pH 7.4 and 20 mM PIPES, 10 mM KCl, pH 6.8, respectively), Zn
2+
 (10 µM FluoZin-1-10 µM 
Zn
2+
, in 10 mM Tris-HCl, pH 7.4), and Ca
2+
. Error bars refer to average standard deviation from 
three separate trials. All work concerning Ca
2+
 Kds can be found in Dr. Anna Wilkins Maniccia’s 
dissertation [37]. 
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CHAPTER 5: ENHANCEMENT OF PROCA1 BY PEGYLATION AND PEPTIDE 
TAGGING 
5.1. Introduction 
5.1.1 PEGylation  
 PEGylation, or addition of a PEG (Polyethylene glycol) chain of various sizes to proteins, 
has drawn attention in therapeutic protein research as an option to increase the benefits and 
development of protein agents. Proteins with PEG chains retain their biological function while 
benefiting from added molecular weight provided by this chain, which decreases renal filtration 
and prolongs retention in the blood. Also, the protein surface is “masked” by this chain, which 
reduces the immunologic response incurred from introducing the protein into a biological 
system.  Another benefit is an increase in the solubility of the protein and the biodistribution due 
to the hydrophilic PEG chain. Furthermore, the protein is protected from protease degradation 
[43; 44; 45] 
 In our laboratory, PEGylation has been performed on members of ProCA1 and has been 
noted to increase the relaxivity and biocompatibility of these agents; PEGylation of ProCA1 has 
been predicted to change the water relaxation rate (unpublished data). The questions raised in 
this chapter are whether PEGylation can be further optimize relaxivity of ProCA1, by varying 
the site of PEGylation among the six lysine residues in CD2.7E15 (positions 43, 45, 47, 51, 66, 
91), and the effect of site-specific PEGylation relative to the location of the metal binding site. 
The hypothesis is that PEGylation near the binding site will increase the relaxivity of ProCA1 by 
increasing the water number and molecular rotational correlation time. This chapter will focus on 
preliminary work with PEGylation of 2 classes of mutated CD2.7E15. The first class, class 1, 
consists of K3CR, K5R, K5166R, and K6691R. K3CR contains 3 mutations from lysine to 
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arginine, specifically on the 3 lysine residues closest to the C terminal in positions 51, 66, 91. 
K5R has 5 mutations from lysine to arginine on all lysines except residue 45. K5166R and 
K6691R have lysine to arginine mutations on sites 51 and 66, and 66 and 91, respectively (Table 
5.1). Changing the lysine to an arginine group spares the arginine from PEGylation so the 
remaining lysine groups are PEGylated. The second class of CD2.7E15 mutations, class 2, 
includes mutations from lysine to cysteine. They include K45C, K51C, and K66C, which each 
have one mutation from lysine to cysteine at sites 45, 51, and 66, respectively. The PEGylation 
agent targets the cysteine for PEGylation (Table 5.1).  
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Table 5. 1 Summarizes the different class 1 and class 2 mutations of CD2.7E15 for PEGylation 
with arginine or cysteine agents. PEG represents the PEGylated residue, R represents the 
arginine mutations which are spared from PEGylation, and C represents cysteine mutations 
which are PEGylated. Also, the current status of each protein is summarized.    
 
Protein 43 45 47 51 66 91 Expressed Purified PEGylated 
K3CR PEG PEG PEG R R R      
K5R R PEG R R R R  (poor)   
K5166R PEG PEG PEG R R PEG      
K6691R PEG PEG PEG PEG R R      
K51C K K K PEG K K       
K66C K K K K PEG K       
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Figure 5. 1 Cartoon summarizing the different class 1 mutations of CD2.7E15 for PEGylation 
with arginine agents relative to the metal binding site of the protein.    
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5.1.2 Enhancement of CD2.7E15 Contrast Agents with Peptide Tags 
 The versatility of CD2.7E15 as a protein construct enables the addition of specific 
peptide tags which may target over-expressed receptors found on cancerous cells. This approach 
enhances the specificity of the contrast agents, which currently are limited to detection of 
material with diameter range above 1-2 mm. Preliminary studies (shown here) show expression 
and purification results from His-CD2.7E15-bom, bombesin tagged 7E15. Bombesin is a gastrin 
releasing peptide analog that targets gastrin-releasing peptide receptors, which are over-
expressed in high levels on the surface of many cancerous cells [2].  This leads to enhancement 
of the image detectable by MRI. Published work shows insertion of a gastrin releasing peptide 
(GRP) (linker and 10 residues from the C terminal of GRP) into different regions in GST-tagged 
CD2.7E15[2].   
5.2 Materials and Methods 
5.2.1 Cloning of Mutants  
 Cloning of K3CR, K5R, K5166R, and K6691R was performed by Yanyi Chen. Cloning 
of  K45C, K51C, K66C was performed under the guidance of Shenghui Xue. First, forward and 
reverse primers, 21-29 nucleotides long, were designed and ordered (from IDT) with the 
appropriate mutation for each protein and considering the melting temperature (Tm) (Table 5.2).  
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Table 5. 2 Designed forward (for) and reverse (rev) primers for cloning of K45C, K51C, and 
K66C.    
 
  
Tm (°C) 
7E15K66C_for Ttggacatatgtaatctgacaagagatg 68 
7E15K66C_rev Gtctccatttgcgtcgatctcaa 68 
   7E15K51C_for Ttttttgtgttcgggagcatttgagat 66 
7E15K51C_rev Ggcttcatcttccttttaaactcg 68 
   7E15K45C_for Aaaaggtgtatgaagccttttttgaaatc 68 
7E15K45C_rev Aaactcggcaaccagggtgct 66 
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 Several samples with primer and DNA of CD2.7E15 underwent PCR (Techne TC 3000). 
First, the strands were denatured at 94 °C for 2 min, then the primers were allowed to bind to the 
DNA at 55 °C (2 min), followed by polymerase extending the primers at 72 °C (10 min). This 
was repeated for 30 cycles. Following the PCR reaction, a DNA gel was used to extract the DNA 
with a Gel Extraction Kit (Qiagen).  
 The DNA was then phosphorylated and ligated. Phosphorylation took place by adding 30 
µL DNA to reaction buffer (5 µL), enzyme (1 µL), ATP (2 µL) and H2O (12 µL), and incubating 
at 37 °C (30 min), followed by 65 °C (20 min). The DNA was then ligated by addition of 1 µL 
ligase and 2 µL ATP and stored at 4 °C overnight.    
 Following phophorylation and ligation, the DNA samples were inserted into DH5α cells, 
and were purified using the Miniprep kit (Qiagen). The DNA from each sample was sequenced 
and the samples containing the mutation were transformed and kept for expression and 
purification.  
 Cloning for His-CD2.7E15-bom was performed by Lixia Wei.  
5.2.2 Expression of K3CR, K5R, K5166R, K6691R, K45C, K51C, K66C, and His-
CD2.7E15-bom 
 A bacterial colony was inoculated and incubated overnight in LB medium with 
2.5 mM ampicillin. Flasks containing 1 L LB medium and 2.5 mM ampicillin received 50 mL of 
the culture grown overnight, and the 1 L flasks were incubated at 37 °C in a shaker (Shaker 
Controlled Environment Incubator). 
The optical density (OD) of each sample at 600 nm was recorded every 30 minutes using 
UV spectrophotometer (Shimadzu Scientific Instruments, Norcross, GA). When the OD reached 
0.6 for BL21 (DE3), Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to the flasks. The 
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BL21 (DE3) strain required 0.25 mM IPTG. The shakers were adjusted 30 °C for the duration of 
expression for K3CR, K5R, K5166R, K6691R, and remained 37°C for K51C, K66C, and His-
CD2.7E15-bom. The cell pellets were collected by centrifugation at 4.410 x 10
3
 g for 20 minutes 
after overnight expression. The cell pellets were stored at -20 °C until purification. KaleidaGraph 
software (Synergy Software, Reading, PA) was used to plot the optical density versus time plots. 
Image J software (Version 1.37) was used to quantify band thickness as a result of expression on 
the 15% acrylamide SDS-PAGE. 
5.2.3 Purification of K3CR, K5166R, K6691R, K51C, and K66C 
 Purification was performed using the refolding method as described in section 2.2.7 with 
modification. Cell pellet from expression (approximately 5 g) was suspended in lysis buffer 
containing PBS. Benzonase nuclease (60 µL) and serine inhibitor PMSF (200 µL) were added. 
The cell pellet was broken using sonication (6 times for 20 seconds each), French press (1500 
psi), or cell disruption. The mixture was then centrifuged (S34 rotor) at 1.2947 x 10
4
 g for 30 
minutes and supernatant was discarded. The cell pellets were then suspended in 20 mL of 2% 
Triton X-100, and centrifuged at 1.2947 x 10
4
 g for 20 minutes between each of three washings. 
Next, the cell pellet was dissolved in 25 mL of 8 M urea (pH 7.3) and stirred overnight at 4 °C to 
completely solubilize the cell pellet.  
The solublized cell pellet was centrifuged for 20 minutes at 1.2947 x 10
4
 g. PBS was then 
added drop-wise for a final concentration of 4 M urea and the solution was stirred for 2 hours. 
Next, the solution was placed in dialysis for 4 hours with 2 M urea, followed by addition of 
proteases (200 µL) and overnight dialysis with 2 L of 10 mM Tris-HCl buffer (pH 7.4). The 
dialysis bag has pores which allow molecules with molecular weight over 3.5 k Da to remain in 
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the bag. The dialysis buffer was changed to 10 mM Tris the following morning, which was 
replaced to gradually remove urea from the solution. Subsequently, the solution was centrifuged 
at 1.2947 x 10
4
 g for 20 minutes, and the supernatant was kept.  
5.2.4 Purification of His-CD2.7E15-bom 
 Cell pellet was dissolved in lysis buffer, sonicated, and centrifuged. The cell pellet was 
kept and dissolved in 50 ml PBS containing 1% Triton x-100, and was then centrifuged for 30 
minutes at 1.2947 x 10
4
 g. This was repeated in triplicate. The cell pellet was dissolved in 1 M 
arginine, and the mixture was left on the agitator at 4 °C overnight. The following day, 
centrifugation was performed (1.2947 x 10
4
 g for 30 minutes) and the supernatant containing 
solubilized protein was collected. Size Exclusion chromatography was performed. SDS-PAGE 
was used to image the supernatants and cell pellets after sonication, washing, and solubilization.  
5.2.5 PEGylation of K51C and K66C  
 Protein (100 µM) was placed in dialysis with PBS and pumped with nitrogen gas. A 
reducing agent, TCEP, was added in 1:10 ratio. The nitrogen gas was stopped and the sample 
was placed on the shaker at 4°C.  The protein was concentrated (Amicon) to a fourth of its initial 
volume, and PEG-Cys reagent ((methyl-PEG12)3-PEG4-Malemide) was added in a 1:10 ratio. 
Nitrogen gas was pumped through the system, which was sealed and placed at 4 °C overnight.  
SDS-PAGE was used to image protein pre-PEGylation and post-PEGylation and the gel was 
stained with iodine to determine if PEGylation was successful. The gels was first washed in 
water, then with BaCl2 (15 min), then with iodine (4 min), and lastly with water. The excess 
protein was removed using the Q column.     
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5.3 Results and Discussion 
5.3.1 Expression and Purification of K3CR, K5R, K5166R, and K6691R  
K3CR, K5R, K5166R, and K6691R were expressed in tag-less vector pET20b with BL21 
(DE3) cell strain at 37 °C overnight. The expression graph is exponential. When the optical 
density (OD) reading reached 0.600 at 600 nm, the flasks received 0.2 mM IPTG (Figure 5.2). 
Following overnight expression the flasks were harvested. SDS-PAGE shows band thickening 
after induction indicating expression of K3CR (Figure 5.2 A), K6691R (Figure 5.2 B), and 
K5166R (Figure 5.2 D). No expression was seen for K5R (Figure 5.2 C).       
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Figure 5.2 Optical density graphs and expression gels for expression in pET20b and BL21 
(DE3) at 30 °C after induction overnight show expression for K3CR, K6691R, and K5166R. (A) 
K3CR. (B) K6691R. (C) K5R. (D) K5166R.  
 
K3CR K6691R
K5R K5166R
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 The refolding method was used to purify K3CR, K5166R, and K6691R. Following 
French press, the proteins were found in inclusion bodies (cell pellets). They were washed with 
2% Triton X-100 to remove lipid-soluble dirt, and were dissolved in 8 M urea. The concentration 
of urea was reduced gradually to 4 M, then to 2 M, and finally 0 M (10 mM Tris-HCl buffer). 
Following centrifugation, the protein was found in the supernatant and after filtration was 
injected into the SP column. The gels show protein in fractions 13 and 17 (Figure 5.3 A, B, and 
C). The concentrations were measured using UV. For K3CR, the yield was 1.2 mg. For K5166R, 
the yield was approximately 3.5 mg, and for K6691R, the yield was 1.7 mg. A terbium titration 
verified that the conformation was stable (not shown).  
 152 
 
 
Figure 5.3 Purification of K3CR, K5166R, and K6691R. (A) K5166R. (B)K6691R.(C) K3CR.  
The gels correspond to the tallest peaks.  
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5.3.2 Expression, Purification, and PEGylation of K51C and K66C 
 K51C and K66C were expressed successfully with BL21 (DE3) cell strain and vector 
pET20b at 37 °C for 4 hours. Expression graphs demonstrate exponential rise in OD. At an OD 
of 0.600 at 600 nm, the flasks received 0.25 mM IPTG. SDS-PAGE shows thickening bands 
with the passage of time, illustrating that the proteins were expressed successfully during 
expression, especially after induction (Figure 5.4). The flasks were harvested after 4 hours.  
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Figure 5.4 Expression of K51C and K66C with BL21 (DE3) cell strain and pET20b vector at 
37°C. (A) Optical density curve indicating is exponential. (B) SDS-PAGE showing presence of 
protein during expression.  
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 Purification was performed via the refolding method described in section 5.2.2. 
Successful purification is shown by SDS-PAGE. The supernatant after French press lacks 
protein, which is present the cell pellet; rather the cell pellet after French press shows protein 
representing inclusion bodies from expression. Following wash with 2% Triton X-100, the cell 
pellet looks cleaner and no protein is lost in the supernatant. After dissolving in 8 M urea the 
protein in the supernatant, and the cell pellet after 8 M urea shows very little insoluble protein 
after refolding. After 10 mM Tris buffer, the supernatant shows clean product ready for injection 
into FPLC (Figure 5.5).  
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Figure 5.5 Purification of K51C and K66C. (A) K66C. (B) K51C. M-marker; 1- supernatant 
after French press shows no protein as it is all in the cell pellet; 2- cell pellet after French press 
shows protein representing inclusion bodies; 3- supernatant after 2% Triton X-100 does not 
contain protein; 4- cell pellet after Triton X-100 contains cell pellet that is cleaner than before 
wash; 5-supernatant after solubilization with 8 M urea shows the protein in the supernatant; 6- 
cell pellet after 8 M urea shows very little insoluble protein after refolding; 7- supernatant after 
10 mM Tris buffer shows clean product ready for injection into FPLC.  
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 The protein (supernatant after 10 mM Tris) was injected into the SP column, following 
adjustment of the pH of proteins to 3.0 with HCl. The peak in fractions 29-31 was found to 
contain protein with high purity (confirmed by SDS-PAGE) (Figure 5.6 and 5.7). The yield of 
K51C was 6.7 mg/ 10 mL injection and the yield for K66C was 5.2 mg/ 10 mL injection.     
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Figure 5.6 Purification of K51C with SP column (flow rate 2 mL/min) 
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Figure 5.7 Purification of K66C with SP column (flow rate 2 mL/min) 
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 Following purification 100 µM protein was PEGylated. Iodine-stained gel shows 
successful PEGylation of K51C and K66C (Figure 5.8). After PEGylation, the protein was 
injected into the Q column to remove excess reagent, because lowing the pH for the SP column 
resulted in precipitation. Following injection into the Q column, the protein was contaminated 
with DNA and was incubated with fresh benzonase nuclease for 4 hours at room temperature.     
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Figure 5.8 Iodine-stained gel depicting PEGylation of K51C and K66C. M-marker; 1-K51C 
before PEGylation; 2-K51C after PEGylation; 3- K66C before PEGylation; 4-K66C after 
PEGylation with (methyl-PEG12)3-PEG4-Maleimide reagent.  
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5.3.3 Expression and Purification of His-CD2.7E15-bom 
 Expression of His-CD2.7E15-bom was performed at 37 °C in BL21 (DE3) cells. Upon 
induction the flasks received 1 mM IPTG, discussed in section 3.3.2 as the optimal amount. 
SDS-PAGE shows an increase in protein production after induction (Figure 5.9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 163 
 
 
 
 
 
 
Figure 5.9 Expression of His-7E15-bom at 37 °C in BL21 (DE3) cells with 1 mM IPTG at 
induction  
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 Purification of His-CD2.7E15-bom was not optimal. After sonication, SDS-PAGE 
showed that the protein was in an inclusion body. Cell pellet was partially dissolved in 50 ml 1% 
Triton x-100, and was then centrifuged for 30 minutes at 1.2947 x 10
4
 g, for a total of 3 washing 
steps. However, after cell pellet was placed in 1M arginine, placed on the agitator overnight at 
4°C, and centrifuged the following day, SDS-PAGE showed low solubilization of the protein in 
arginine, represented by a thin band in the supernatant. Size Exclusion chromatography was 
performed which shows almost no protein on the SDS-PAGE.   
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Figure 5.10 Size Exclusion chromatography shows almost no product of His-CD2.7E15-bom 
when fractions 7-9 are visualized on SDS-PAGE.  
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5.4 Conclusions and Future Work 
 Modification of contrast agents by PEGylation or addition of peptide chains has been 
predicted to enhance the effectiveness of the contrast agents. Preliminary studies show that 
optimization of expression, purification, and PEGylation is needed.  Expression of arginine 
mutants (class 1) was low, yet successful for K3CR, K5166R, and K6691R. Yields after 
purification were low (1.7-3.2 mg) because expression was low. K5R did not express well, and 
conditions for expression need to be optimized. After purification yield is increased, then a 
sufficient amount of protein will be available for PEGylation, relaxivity studies, and structural 
examination as contrast agents.  
 Expression and purification of cysteine mutants (class 2) was successful with yields as 
high as 5.2-6.7 mg per 10 mL injection.  PEGylation was successful; additional dosages of 
benzonase nuclease may help to reduce contamination by DNA for further optimization of the 
protocol. Once contamination is removed, the PEGylated protein can be used further in structural 
and relaxivity studies as a contrast agent.    
 Preliminary expression and purification studies of His-CD2.7E15-bom showed successful 
expression with an optimized level of IPTG, yet purification in low yield. Later studies 
performed by Lixia Wei show higher purification yield using a GST tag. Furthermore, the 
protein has been studied as a contrast agent bonded to a GRP targeting sequence (instead of the 
analog, bombesin) and has shown high relaxivity as a contrast agent [2].  
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CHAPTER 6: SIGNIFICANCE OF THIS WORK 
  MRI is an excellent diagnostic tool, providing a wealth of information about tissues in 
vivo and without the use of radiation.  Contrast agents used to enhance MRI have several 
limitations that have led to the search of new contrast agent. We propose a protein-based contrast 
agent, designed by inserting a metal binding site into CD2.   Scaled up production of these 
proteins is necessary for structural, functional, therapeutic, and in vivo analysis, studies which 
are necessary to bring the contrast agents to a clinical level.  The objective of this thesis was to 
examine expression and purification conditions for CD2.7E15 and variants, because these 
conditions are vital to maximizing the production of CD2.6D31, CD2.7E15, and CD2.7E15 
charged variants with the least time and effort. Determination of high efficiency expression and 
purification method allows further evaluation of various engineered proteins as suitable contrast 
agents by relaxivity and structural studies.  
 To begin the protein mass-production studies, wild type CD2, CD2.7E15, CD2.6D31 
were chosen as models to reevaluate the old expression and purification procedures. They were 
expressed as a fusion protein with the Glutathione-S-Transferase (GST) affinity tag, with three 
temperatures and three cell strains, and were purified using affinity column chromatography. 
Optimal expression conditions were determined, which were different for each CD2 variant. 
Furthermore, the quantity of soluble protein produced during expression was variable for each 
protein, and depended on the temperature and cell strain as well.   
 Next, GST purification was examined in light of expression. Affinity tag GST folding 
was found to largely depend on the engineered protein folding (which depended on expression). 
Correlation between beads binding assay and GST enzymatic activity indicate that high 
enzymatic activity in GST resulted in larger quantity of fusion protein binding to the affinity 
 168 
 
columns. High purification level is achievable when the quality of GST folding is high, which is 
tied back to the expression conditions. This information helped determine which conditions are 
conducive to producing soluble protein and which encouraged inclusion body formation in the 
three engineered proteins. This was a powerful database for later selection of expression 
conditions for CD2.7E15 charged variants (chapter 2).  
 A rapid, effective method for generating high yield of CD2.7E15 has been established by 
generating inclusion bodies (chapter 2) and testing two ways to purify them. The first included 
solubilization in arginine followed by denaturation in urea. However, the protein did not 
solubilize well in arginine, as indicated by SDS-PAGE, and only a small quantity of protein was 
extracted. Purification by direct immersion of cell pellet in 8 M urea at room temperature showed 
a high level of solubilized protein. Structural studies with CD and tryptophan fluorescence 
provide evidence that suggests that the refolding method can reliably generate protein that does 
not lose its native conformation. The theoretical yield for a liter of expressed cell culture has 
risen impressively to 156 mg -234 mg pure protein from 1 L expressed cell pellet, a tremendous 
improvement from traditional GST purification (chapter 3). 
 Using this high-yield purification method, it was possible to generate large quantities of 
protein for structural, metal binding, relaxivity studies, in vivo studies (future), and determination 
of the suitability of charged variants of ProCA1 as contrast agents. Charged variants had a higher 
selectivity for Gd
3+
  over Zn
2+
 and Ca
2+
 , suggesting that these proteins will bind to metals such 
as Gd
3+
 and lanthanides with much higher affinity than to physiological metals. A strong binding 
affinity to Gd
3+
 is an important quality for a contrast agent to reduce the toxic effects of free 
Gd
3+
. Strong binding is advantageous to enhance imaging as well. The metal selectivity of Gd
3+
 
over Zn
2+
 or Ca
2+
 was also found to be significantly higher. Among the different charged 
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variants, the difference in binding affinity was small. The relaxivities of CD2.7E15 and the 
charged variants were similar to each other but overall were significantly higher than the 
relaxivity of Gd-DTPA.  We conclude that -4 and -5 charged variants are suitable candidates for 
the next contrast agents based on metal selectivity and high relaxivity (chapter 4). 
   Research on improving contrast agents is focused on insertion of PEG chains or peptide 
tags (bombesin) in proteins. These options were studied with ProCA1 as possible ways to 
enhance protein-based contrast agents. Preliminary studies show that future work is needed to 
further develop this approach. Arginine mutants (K3CR, K5166R, and K6691R) were expressed, 
albeit in low quantities.  The mutants were purified successfully in low yield (1.7-3.2 mg), but 
the yield requires optimization for continued studies of this protein by PEGylation, relaxivity 
studies, and structural examination. Expression and purification of cysteine mutants was 
successful with yields as high as 5.2-6.7 mg per 10 mL injection.  Additionally, PEGylation was 
successful, except that the product was contaminated by DNA. Optimization of the purification 
procedure will allow the PEGylated protein to be further used in structural and relaxivity studies.  
Preliminary expression and purification studies of His-CD2.7E15-bom led way for the protein to 
be studied as a contrast agent bonded to a GRP targeting sequence (Lixia Wei) [2], which has 
shown high relaxivity as a contrast agent (chapter 5). The studies in this thesis have contributed 
to the growing field of MRI research by providing more candidates for protein-based contrast 
agents.   
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